{"current_page":1,"data":[{"id":4051,"created_at":"2026-11-18T16:10:09.000000Z","updated_at":"2026-11-18T16:11:56.000000Z","deleted_at":null,"active_date":"2026-11-18 16:11:56","non_gateway_datasets":[],"non_gateway_applicants":["Jiayue Gu"],"funders_and_sponsors":[""],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Understanding how genes influence the development and progression of long-term liver disease","project_id_text":"OFHS260187","organisation_name":"University of Edinburgh","organisation_sector":"Academic Institute","lay_summary":"Our aim is to identify genes that may help explain why some people develop long-term liver disease and why the disease becomes more severe in some people than in others. We are particularly interested in liver scarring, which can build up over time and stop the liver from working properly.\nWe will use existing research data from liver tissue to understand how inherited genetic differences affect the activity of genes in different types of liver cells. We will then use these findings to estimate gene activity from Our Future Health participants\u2019 genetic information and examine its relationship with their health records.\nWe will address three questions:\n- Which genes are linked to developing liver disease, hospital admission for liver disease, or death from liver disease?\n- Which types of liver cells are these genes active in?\n- Do these genes show similar patterns across different causes and stages of liver disease?\nThe findings will help us select promising genes for further research into treatments and ways to identify people at greater risk. This study will generate evidence to guide future research; it will not directly test new treatments. Long-term liver disease can lead to scarring that prevents the liver from working properly. However, the disease progresses differently between people, and it remains difficult to predict who will become seriously ill. A better understanding of the genes involved could help guide research into treatments and earlier identification of people at risk.\nOur existing research has examined gene activity in individual liver cells, revealing cell types and biological processes linked to scarring. However, these tissue studies involve relatively small numbers of people and usually capture only one point in time. They cannot establish which changes contribute to worsening disease and which are consequences of existing damage.\nWe will build on this work by linking inherited genetic differences to estimated gene activity in different liver cell types. We will then use genetic information and linked health records from Our Future Health to investigate how these estimates relate to liver disease and its complications in a much larger population.\nComparing the findings with other liver tissue datasets will help us prioritise genes for further investigation. This approach could strengthen the evidence for potential treatment targets and improve understanding of why liver disease develops and worsens.","technical_summary":null,"latest_approval_date":"2026-11-16 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":null,"public_benefit_statement":"Long-term liver disease can cause serious illness and shorten lives. Patients need better treatments to prevent liver scarring and better ways to identify who is likely to become seriously ill.\n\nOur study will investigate genes that may contribute to liver disease and its progression. By identifying promising genes and the liver cells in which they act, we hope to help researchers choose targets for developing medicines that could prevent or slow liver damage.\n\nThe findings could also support future research into identifying people at greater risk of severe liver disease. In time, this could help doctors offer closer monitoring and earlier care to those most likely to benefit.\n\nWe will examine findings across different causes of liver disease to understand whether they point to shared processes or differences that could matter for future treatments.\n\nThese benefits will require further research and testing before they can be used in healthcare. The immediate benefit will be stronger evidence to guide that work. We plan to share our findings through scientific publications and summaries written for the public.","data_sensitivity_level":null,"project_start_date":"2026-11-16 12:00:00","project_end_date":null,"access_date":null,"accredited_researcher_status":null,"confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":null,"legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":null,"organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":null,"access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":281,"team_id":86,"application_id":null,"applicant_id":null,"sector_id":3,"status":"ACTIVE","datasets":[{"id":888,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:45:29.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:45:29.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:44","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Baseline Health Questionnaire Data","dataset_version_ids":[980]},{"id":889,"datasetid":"5255a7ee-e9da-4d77-80bc-3e1a4bf35c50","pid":"723886b5-1229-4e8e-811f-1879ebcb365d","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:43:01.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:43:01.000000Z","deleted_at":null,"active_date":"2025-04-29 10:45:48","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Linked Health Records Data","dataset_version_ids":[888]},{"id":890,"datasetid":"5dcd7eb3-6b4a-4c11-9b8c-63bc7d0c0026","pid":"b9ac6f4a-06fc-4a86-b327-3b484acd81f9","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:44:35.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:44:35.000000Z","deleted_at":null,"active_date":"2026-06-01 11:03:04","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Genotype Data","dataset_version_ids":[981]},{"id":993,"datasetid":null,"pid":"f3e1819e-ee38-4ded-b747-06d9e40f09c1","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-11-26T13:59:02.000000Z","updated":"2026-06-08T09:43:46.000000Z","submitted":"2024-11-26 13:59:02","published":null,"created_at":"2024-11-26T13:59:02.000000Z","updated_at":"2026-06-08T09:43:46.000000Z","deleted_at":null,"active_date":"2025-06-12 14:36:43","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Clinical Measurements Data","dataset_version_ids":[1140]},{"id":1769,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":1067,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2026-06-01T10:18:57.000000Z","updated":"2026-06-04T13:44:39.000000Z","submitted":"2026-06-01 10:18:57","published":null,"created_at":"2026-06-01T10:18:57.000000Z","updated_at":"2026-06-04T13:44:39.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:54","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Participant Geographies Data","dataset_version_ids":[2047]}],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false},"team":{"id":86,"pid":"7edbcc67-610e-4234-a7ea-47e0e7f0b64c","created_at":"2024-10-08T11:18:56.000000Z","updated_at":"2026-06-19T09:14:29.000000Z","deleted_at":null,"name":"Our Future Health","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":"\/teams\/1729869846_ofh_logo_hdruk_2000x1000.jpg","member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":true,"is_question_bank":false,"is_provider":false,"url":null,"introduction":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health is the UK's largest ever health research programme. It is designed to enable the discovery and testing of more effective approaches to prevention, earlier detection and treatment of diseases.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"The programme is collecting and linking multiple sources of health and health-relevant information, including genetic data, across a cohort of up to 5 million people. It is recruiting participants from all ages, backgrounds and communities to create a cohort that truly reflects the UK population.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health will create a world-leading resource for researchers from universities, charities, the NHS and companies involved in health research to undertake discovery research on early indicators of disease. Researchers will also have the opportunity to re-contact participants on a risk-stratified basis for secondary studies.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Find out more on the Our Future Health website: \"},{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/ourfuturehealth.org.uk\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/ourfuturehealth.org.uk\/\"}]}]}","dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Our Future Health dataset, please use the following link.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"laravel_through_key":4051,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false}],"applications":[]},{"id":4050,"created_at":"2026-11-18T16:10:09.000000Z","updated_at":"2026-11-18T16:11:31.000000Z","deleted_at":null,"active_date":"2026-11-18 16:11:31","non_gateway_datasets":[],"non_gateway_applicants":["Cameron Razieh"],"funders_and_sponsors":[""],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Can lifestyle behaviours better predict deaths and long-term health conditions","project_id_text":"OFHS260003","organisation_name":"University of Leicester","organisation_sector":"Academic Institute","lay_summary":"This study aims to look at whether a person\u2019s physical activity, behaviours and function can help us better predict their future health. We want to see if adding information about how much, and how easily, a person moves can give us a clearer picture of their risk of dying or developing health conditions, rather than just looking at factors they can\u2019t change, like their age or sex. Heart disease and cancer are the two leading causes of long-term illness and death worldwide, putting a significant strain on our health services. We know that lifestyle habits, especially how much and how we move, has a huge impact on our health.\n\nFor a long time, doctors have used health \"calculators\" to estimate a person\u2019s risk of heart disease or dying early. These tools usually look at things we cannot change, like our age and sex. While lifestyle habits have a big impact on our health, they are not typically included in these standard health calculators. Recent research shows that simple measures of movement, such as how fast a person walks, is a strong sign of overall health. However, we don't yet know if adding this movement information to traditional health calculators actually makes them more accurate.\n\nThis study aims to find the best way to include a person's activity levels in these health calculators. By doing so, we hope to provide a clearer, more personalised picture of a person's future health, helping to improve disease prevention and early medical support.","technical_summary":null,"latest_approval_date":"2026-07-24 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":null,"public_benefit_statement":"Increasing evidence shows that metrics reflecting physical behaviour (e.g., physical activity) and physical function (e.g., walking pace) have demonstrated strong ability in predicting a person\u2019s risk of getting ill or dying. If appropriately linked with clinical records, lifestyle data could significantly enhance traditional \u201crisk calculators\u201d, offering a more complete view of health and enabling the generation of a \u201crisk calculator\u201d that is more accurate and specific to the individual to support early identification and prevention of disease.\n\nMore accurate measure of health risk could lead to identifying people at higher risk of health problems and helping people live longer and healthier lives. This research could change and improve how to identify people at risk of future health problems. By proving that simple and daily movement data is an important health indicator, we can help develop better risk \u201ccalculators\u201d.\nInstead of only looking at risk factors that patients can't change, we could additionally use a person\u2019s walking pace and activity levels to provide better, more tailored advice. This could also help people stay healthier for longer by focusing on habits they can control to improve their long-term health.","data_sensitivity_level":null,"project_start_date":"2026-11-16 12:00:00","project_end_date":null,"access_date":null,"accredited_researcher_status":null,"confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":null,"legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":null,"organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":null,"access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":281,"team_id":86,"application_id":null,"applicant_id":null,"sector_id":3,"status":"ACTIVE","datasets":[{"id":888,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:45:29.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:45:29.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:44","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Baseline Health Questionnaire Data","dataset_version_ids":[980]},{"id":889,"datasetid":"5255a7ee-e9da-4d77-80bc-3e1a4bf35c50","pid":"723886b5-1229-4e8e-811f-1879ebcb365d","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:43:01.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:43:01.000000Z","deleted_at":null,"active_date":"2025-04-29 10:45:48","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Linked Health Records Data","dataset_version_ids":[888]},{"id":890,"datasetid":"5dcd7eb3-6b4a-4c11-9b8c-63bc7d0c0026","pid":"b9ac6f4a-06fc-4a86-b327-3b484acd81f9","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:44:35.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:44:35.000000Z","deleted_at":null,"active_date":"2026-06-01 11:03:04","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Genotype Data","dataset_version_ids":[981]},{"id":993,"datasetid":null,"pid":"f3e1819e-ee38-4ded-b747-06d9e40f09c1","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-11-26T13:59:02.000000Z","updated":"2026-06-08T09:43:46.000000Z","submitted":"2024-11-26 13:59:02","published":null,"created_at":"2024-11-26T13:59:02.000000Z","updated_at":"2026-06-08T09:43:46.000000Z","deleted_at":null,"active_date":"2025-06-12 14:36:43","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Clinical Measurements Data","dataset_version_ids":[1140]},{"id":1769,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":1067,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2026-06-01T10:18:57.000000Z","updated":"2026-06-04T13:44:39.000000Z","submitted":"2026-06-01 10:18:57","published":null,"created_at":"2026-06-01T10:18:57.000000Z","updated_at":"2026-06-04T13:44:39.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:54","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Participant Geographies Data","dataset_version_ids":[2047]}],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false},"team":{"id":86,"pid":"7edbcc67-610e-4234-a7ea-47e0e7f0b64c","created_at":"2024-10-08T11:18:56.000000Z","updated_at":"2026-06-19T09:14:29.000000Z","deleted_at":null,"name":"Our Future Health","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":"\/teams\/1729869846_ofh_logo_hdruk_2000x1000.jpg","member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":true,"is_question_bank":false,"is_provider":false,"url":null,"introduction":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health is the UK's largest ever health research programme. It is designed to enable the discovery and testing of more effective approaches to prevention, earlier detection and treatment of diseases.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"The programme is collecting and linking multiple sources of health and health-relevant information, including genetic data, across a cohort of up to 5 million people. It is recruiting participants from all ages, backgrounds and communities to create a cohort that truly reflects the UK population.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health will create a world-leading resource for researchers from universities, charities, the NHS and companies involved in health research to undertake discovery research on early indicators of disease. Researchers will also have the opportunity to re-contact participants on a risk-stratified basis for secondary studies.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Find out more on the Our Future Health website: \"},{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/ourfuturehealth.org.uk\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/ourfuturehealth.org.uk\/\"}]}]}","dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Our Future Health dataset, please use the following link.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"laravel_through_key":4050,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false}],"applications":[]},{"id":4049,"created_at":"2026-11-18T16:10:09.000000Z","updated_at":"2026-11-18T16:11:06.000000Z","deleted_at":null,"active_date":"2026-11-18 16:11:06","non_gateway_datasets":[],"non_gateway_applicants":["Stuart Macgregor"],"funders_and_sponsors":[""],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Finding genes and shared genetic causes across many common health conditions","project_id_text":"OFHS260103","organisation_name":"QIMR Berghofer","organisation_sector":"Academic Institute","lay_summary":"The aim of this study is to use the genetic and health information in Our Future Health to better understand why people differ in their risk of common diseases, and to use that understanding to predict risk more accurately. We will address four questions. First, which specific genetic differences are linked to each of a wide range of conditions, for example eye disease such as glaucoma, several cancers, heart disease and mental health conditions. Second, to what extent do different conditions share the same underlying genetic causes. Third, which risk factors, such as body weight, blood pressure or blood markers, are likely to actually cause disease rather than simply being associated with it. Fourth, how well can we predict who is at higher risk of disease by combining genetic information with other health data such as medical history, medicines, physical measurements and laboratory results. Our genes help explain why some people develop diseases like heart disease, cancer, eye disease or mental health conditions, and this study will search for the genes involved and find out which ones are shared across different conditions.\nMost common diseases are shaped by many small genetic differences, working alongside lifestyle and environment. Researchers have found some of these genetic differences, but many are still unknown, because finding them needs very large numbers of people. There is also growing evidence that conditions which seem unrelated can share the same genetic causes.\nThrough this study, we will find new genetic links to disease. We will measure how much different conditions overlap genetically. We will test which risk factors are likely to cause disease. And we will build tools that predict who is at higher risk.\nUnderstanding the genes behind disease can reveal how illnesses start and point to new treatments. It can show which risk factors are worth changing. It can also help doctors find people at higher risk earlier, so they can act sooner.","technical_summary":null,"latest_approval_date":"2026-08-25 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":null,"public_benefit_statement":"Better understanding of the genetic causes of disease can benefit the public in several ways. Identifying the specific genes and biological pathways involved in a condition can reveal how the disease develops and highlight possible targets for new treatments. Finding that two apparently different conditions share genetic causes can change how diseases are classified and understood, and can suggest that a treatment used for one condition may help another. Working out which risk factors are likely to actually cause disease, rather than simply being linked to it, can provide evidence to support public health advice and policy, particularly where a risk factor can be changed. Finally, combining genetic information with other health data allows more accurate prediction of who is at higher risk of a given disease. More accurate risk prediction can support earlier detection, more targeted screening and more efficient use of health services. The findings will be shared through scientific publications and summaries so that other researchers, clinicians and the public can benefit.","data_sensitivity_level":null,"project_start_date":"2026-11-16 12:00:00","project_end_date":null,"access_date":null,"accredited_researcher_status":null,"confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":null,"legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":null,"organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":null,"access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":281,"team_id":86,"application_id":null,"applicant_id":null,"sector_id":3,"status":"ACTIVE","datasets":[{"id":888,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:45:29.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:45:29.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:44","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Baseline Health Questionnaire Data","dataset_version_ids":[980]},{"id":889,"datasetid":"5255a7ee-e9da-4d77-80bc-3e1a4bf35c50","pid":"723886b5-1229-4e8e-811f-1879ebcb365d","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:43:01.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:43:01.000000Z","deleted_at":null,"active_date":"2025-04-29 10:45:48","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Linked Health Records Data","dataset_version_ids":[888]},{"id":890,"datasetid":"5dcd7eb3-6b4a-4c11-9b8c-63bc7d0c0026","pid":"b9ac6f4a-06fc-4a86-b327-3b484acd81f9","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:44:35.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:44:35.000000Z","deleted_at":null,"active_date":"2026-06-01 11:03:04","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Genotype Data","dataset_version_ids":[981]},{"id":993,"datasetid":null,"pid":"f3e1819e-ee38-4ded-b747-06d9e40f09c1","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-11-26T13:59:02.000000Z","updated":"2026-06-08T09:43:46.000000Z","submitted":"2024-11-26 13:59:02","published":null,"created_at":"2024-11-26T13:59:02.000000Z","updated_at":"2026-06-08T09:43:46.000000Z","deleted_at":null,"active_date":"2025-06-12 14:36:43","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Clinical Measurements Data","dataset_version_ids":[1140]},{"id":1769,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":1067,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2026-06-01T10:18:57.000000Z","updated":"2026-06-04T13:44:39.000000Z","submitted":"2026-06-01 10:18:57","published":null,"created_at":"2026-06-01T10:18:57.000000Z","updated_at":"2026-06-04T13:44:39.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:54","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Participant Geographies Data","dataset_version_ids":[2047]}],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false},"team":{"id":86,"pid":"7edbcc67-610e-4234-a7ea-47e0e7f0b64c","created_at":"2024-10-08T11:18:56.000000Z","updated_at":"2026-06-19T09:14:29.000000Z","deleted_at":null,"name":"Our Future Health","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":"\/teams\/1729869846_ofh_logo_hdruk_2000x1000.jpg","member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":true,"is_question_bank":false,"is_provider":false,"url":null,"introduction":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health is the UK's largest ever health research programme. It is designed to enable the discovery and testing of more effective approaches to prevention, earlier detection and treatment of diseases.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"The programme is collecting and linking multiple sources of health and health-relevant information, including genetic data, across a cohort of up to 5 million people. It is recruiting participants from all ages, backgrounds and communities to create a cohort that truly reflects the UK population.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health will create a world-leading resource for researchers from universities, charities, the NHS and companies involved in health research to undertake discovery research on early indicators of disease. Researchers will also have the opportunity to re-contact participants on a risk-stratified basis for secondary studies.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Find out more on the Our Future Health website: \"},{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/ourfuturehealth.org.uk\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/ourfuturehealth.org.uk\/\"}]}]}","dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Our Future Health dataset, please use the following link.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"laravel_through_key":4049,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false}],"applications":[]},{"id":4052,"created_at":"2026-11-18T16:10:09.000000Z","updated_at":"2026-11-18T16:10:39.000000Z","deleted_at":null,"active_date":"2026-11-18 16:10:39","non_gateway_datasets":[],"non_gateway_applicants":["Colin Mclean"],"funders_and_sponsors":[""],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Using Our Future Health to explore how genes, lifestyle, and social and environmental factors shape bowel cancer risk among younger adults in the UK.","project_id_text":"OFHS260152","organisation_name":"Cancer Research (CRUK) Scotland Institute","organisation_sector":"Independent Sector Organisation","lay_summary":"Although bowel cancer usually affects older people, there is an alarming increase in younger adults (under 50), and we do not fully understand why. Part of the reason lies in the genes people inherit. But it is also shaped by our general environment: where we live, how affluent we are, the air we breathe, the food available to us, and our weight and general health.\n\nOur aim is to understand why bowel cancer is rising among younger adults, and to find out who is most at risk. Using Our Future Health, a new research programme which brings together genetic, health, lifestyle and location information from a large, diverse group of volunteers, we will ask three questions:\n\nIs the rise happening in people with a family history of bowel cancer or with genetic inherited risk, or in those without?\nDo income, neighbourhood, access to healthy food and air quality affect risk?\nDo weight and other aspects of metabolic health in young adulthood increase risk?\n\nBy answering these questions, we hope to identify younger adults at higher risk. Consequently, medical professionals can offer tailored advice or earlier checks to those who would benefit most, before the age when NHS screening usually begins. Bowel cancer has been rising in adults under 50 across many countries since the 1990s. This increase is real, not simply the result of better detection, and it points to something in modern life affecting people from childhood and early adulthood onwards. Over the same period, metabolic conditions, including obesity, have become far more common among young people.\n\nProgress has been held back by two problems. First, studies often lump all younger patients together, mixing those with a strong family history of bowel cancer and those without, even though the causes may differ. Second, the everyday things that shape our health, such as income, neighborhood, air quality, diet, metabolic health and weight, are rarely studied together on a large scale.\n\nIn this study, we will use Our Future Health, which combines genetic, health, lifestyle, and location information from a very large, diverse group of people. This lets us separate inherited risks from risk linked to lifestyle, surroundings, and weight-related health.\n\nBy doing this, we expect to identify which younger adults are most at risk and why. This could help doctors offer earlier advice or checks to those who would benefit most, and guide future research into preventing the disease.","technical_summary":null,"latest_approval_date":"2026-09-09 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":null,"public_benefit_statement":"Bowel cancer diagnosed before 50 is often found late, partly because younger adults fall outside the age range for NHS bowel screening, and neither they nor their doctors expect the disease. The number of younger people affected is rising, yet there is currently no way to tell who is most at risk. This is the gap our study addresses.\n\nBy separating risk that runs in families from risk linked to inherited circumstances, lifestyle and weight-related health, we aim to identify the groups of younger adults at highest risk, and to understand which of these causes matter most. This could benefit the public in several ways. It could help doctors identify which patients are most at risk, and may provide opportunities for targeted prevention or screening checks to those most likely to benefit, before the usual screening age. It could point to causes that can be changed, guiding prevention. Studying where people live and how affluent they are, could show whether bowel cancer risk falls unequally across society, helping make any future prevention fairer.\n\nThis is of great importance and interest to the public. These findings will be shared openly to support wider research into preventing and detecting bowel cancer earlier.","data_sensitivity_level":null,"project_start_date":"2026-11-16 12:00:00","project_end_date":null,"access_date":null,"accredited_researcher_status":null,"confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":null,"legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":null,"organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":null,"access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":281,"team_id":86,"application_id":null,"applicant_id":null,"sector_id":5,"status":"ACTIVE","datasets":[{"id":888,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:45:29.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:45:29.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:44","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Baseline Health Questionnaire Data","dataset_version_ids":[980]},{"id":889,"datasetid":"5255a7ee-e9da-4d77-80bc-3e1a4bf35c50","pid":"723886b5-1229-4e8e-811f-1879ebcb365d","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:43:01.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:43:01.000000Z","deleted_at":null,"active_date":"2025-04-29 10:45:48","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Linked Health Records Data","dataset_version_ids":[888]},{"id":890,"datasetid":"5dcd7eb3-6b4a-4c11-9b8c-63bc7d0c0026","pid":"b9ac6f4a-06fc-4a86-b327-3b484acd81f9","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:44:35.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:44:35.000000Z","deleted_at":null,"active_date":"2026-06-01 11:03:04","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Genotype Data","dataset_version_ids":[981]},{"id":993,"datasetid":null,"pid":"f3e1819e-ee38-4ded-b747-06d9e40f09c1","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-11-26T13:59:02.000000Z","updated":"2026-06-08T09:43:46.000000Z","submitted":"2024-11-26 13:59:02","published":null,"created_at":"2024-11-26T13:59:02.000000Z","updated_at":"2026-06-08T09:43:46.000000Z","deleted_at":null,"active_date":"2025-06-12 14:36:43","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Clinical Measurements Data","dataset_version_ids":[1140]},{"id":1769,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":1067,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2026-06-01T10:18:57.000000Z","updated":"2026-06-04T13:44:39.000000Z","submitted":"2026-06-01 10:18:57","published":null,"created_at":"2026-06-01T10:18:57.000000Z","updated_at":"2026-06-04T13:44:39.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:54","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Participant Geographies Data","dataset_version_ids":[2047]}],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false},"team":{"id":86,"pid":"7edbcc67-610e-4234-a7ea-47e0e7f0b64c","created_at":"2024-10-08T11:18:56.000000Z","updated_at":"2026-06-19T09:14:29.000000Z","deleted_at":null,"name":"Our Future Health","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":"\/teams\/1729869846_ofh_logo_hdruk_2000x1000.jpg","member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":true,"is_question_bank":false,"is_provider":false,"url":null,"introduction":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health is the UK's largest ever health research programme. It is designed to enable the discovery and testing of more effective approaches to prevention, earlier detection and treatment of diseases.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"The programme is collecting and linking multiple sources of health and health-relevant information, including genetic data, across a cohort of up to 5 million people. It is recruiting participants from all ages, backgrounds and communities to create a cohort that truly reflects the UK population.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health will create a world-leading resource for researchers from universities, charities, the NHS and companies involved in health research to undertake discovery research on early indicators of disease. Researchers will also have the opportunity to re-contact participants on a risk-stratified basis for secondary studies.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Find out more on the Our Future Health website: \"},{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/ourfuturehealth.org.uk\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/ourfuturehealth.org.uk\/\"}]}]}","dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Our Future Health dataset, please use the following link.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"laravel_through_key":4052,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false}],"applications":[]},{"id":4045,"created_at":"2026-11-18T15:19:36.000000Z","updated_at":"2026-11-18T15:24:25.000000Z","deleted_at":null,"active_date":"2026-11-18 15:24:25","non_gateway_datasets":[],"non_gateway_applicants":["Maciej Tomaszewski"],"funders_and_sponsors":[""],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Integrating genetic, lifestyle and healthcare information to uncover causes of heart and kidney diseases","project_id_text":"OFHS260067","organisation_name":"The University of Manchester","organisation_sector":"Academic Institute","lay_summary":"Heart and kidney diseases are major global health problems and leading causes of early death. In the UK, heart disease alone accounts for one in four annual deaths, while chronic kidney disease affects almost one in ten people. High blood pressure is an important risk factor for both conditions. Moreover, high blood pressure and chronic kidney disease each worsen the other and both increase the overall risk of heart disease.\nNew and better treatment strategies are urgently needed to prevent or reverse these complex diseases but these can only be uncovered through furthering our understanding of their causes. How these diseases develop and progress is affected by changes to our genetic code inherited at birth (DNA) as well as our environment (including our lifestyle choices). Our study aims to look at these to provide a better understanding of the causes of heart and kidney diseases, as well as predict their complications (such as heart failure) before they happen. Together, this will allow us to tailor treatments to individuals who are at greater risk of developing these diseases. To do this, we need to look closer at how our genetics, environment and lifestyle work together to make some people more likely to develop these diseases than others and how these factors affect the pace at which these diseases progress.\n\nOur goals are to identify which genes influence these conditions, see how they act in people under different genetic or medical circumstances and explore how our environment and lifestyle affect disease risk by changing how these genes behave. For instance, due to a mix of genetic, environmental and lifestyle factors, two individuals with the same high blood pressure may have very different health outcomes: one developing severe heart and kidney failure whilst the other remains stable.\n\nTo understand these differences, we will use the wealth of medical and genetics data in Our Future Health. This will allow us to identify how genetic, environmental and lifestyle factors combine to drive heart and kidney disease development and progression, discover new markers to detect these diseases in their early stages, and find disease-associated genes that can be targeted in future treatments.","technical_summary":null,"latest_approval_date":"2026-08-18 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":null,"public_benefit_statement":"By improving our understanding of their causes, we aim to promote the development of new, more effective treatment options and strategies for the prevention and management of heart and kidney diseases.\n\nWe want to uncover how specific combinations of genetic, environmental and lifestyle factors become protective or harmful. This will allow us to create tools to predict how these diseases and their complications develop and progress, as well as find new targets for future treatments and better advise patients with heart and kidney disease on their personal management.","data_sensitivity_level":null,"project_start_date":"2026-10-30 12:00:00","project_end_date":null,"access_date":null,"accredited_researcher_status":null,"confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":null,"legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":null,"organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":null,"access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":281,"team_id":86,"application_id":null,"applicant_id":null,"sector_id":3,"status":"ACTIVE","datasets":[{"id":888,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:45:29.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:45:29.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:44","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Baseline Health Questionnaire Data","dataset_version_ids":[980]},{"id":889,"datasetid":"5255a7ee-e9da-4d77-80bc-3e1a4bf35c50","pid":"723886b5-1229-4e8e-811f-1879ebcb365d","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:43:01.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:43:01.000000Z","deleted_at":null,"active_date":"2025-04-29 10:45:48","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Linked Health Records Data","dataset_version_ids":[888]},{"id":890,"datasetid":"5dcd7eb3-6b4a-4c11-9b8c-63bc7d0c0026","pid":"b9ac6f4a-06fc-4a86-b327-3b484acd81f9","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:44:35.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:44:35.000000Z","deleted_at":null,"active_date":"2026-06-01 11:03:04","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Genotype Data","dataset_version_ids":[981]},{"id":993,"datasetid":null,"pid":"f3e1819e-ee38-4ded-b747-06d9e40f09c1","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-11-26T13:59:02.000000Z","updated":"2026-06-08T09:43:46.000000Z","submitted":"2024-11-26 13:59:02","published":null,"created_at":"2024-11-26T13:59:02.000000Z","updated_at":"2026-06-08T09:43:46.000000Z","deleted_at":null,"active_date":"2025-06-12 14:36:43","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Clinical Measurements Data","dataset_version_ids":[1140]}],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false},"team":{"id":86,"pid":"7edbcc67-610e-4234-a7ea-47e0e7f0b64c","created_at":"2024-10-08T11:18:56.000000Z","updated_at":"2026-06-19T09:14:29.000000Z","deleted_at":null,"name":"Our Future Health","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":"\/teams\/1729869846_ofh_logo_hdruk_2000x1000.jpg","member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":true,"is_question_bank":false,"is_provider":false,"url":null,"introduction":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health is the UK's largest ever health research programme. It is designed to enable the discovery and testing of more effective approaches to prevention, earlier detection and treatment of diseases.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"The programme is collecting and linking multiple sources of health and health-relevant information, including genetic data, across a cohort of up to 5 million people. It is recruiting participants from all ages, backgrounds and communities to create a cohort that truly reflects the UK population.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health will create a world-leading resource for researchers from universities, charities, the NHS and companies involved in health research to undertake discovery research on early indicators of disease. Researchers will also have the opportunity to re-contact participants on a risk-stratified basis for secondary studies.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Find out more on the Our Future Health website: \"},{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/ourfuturehealth.org.uk\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/ourfuturehealth.org.uk\/\"}]}]}","dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Our Future Health dataset, please use the following link.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"laravel_through_key":4045,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false}],"applications":[]},{"id":4048,"created_at":"2026-11-18T15:19:37.000000Z","updated_at":"2026-11-18T15:22:45.000000Z","deleted_at":null,"active_date":"2026-11-18 15:22:45","non_gateway_datasets":[],"non_gateway_applicants":["Gibran Hemani"],"funders_and_sponsors":[""],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Developing software tools that help the scientific community link differences between people\u2019s DNA with health outcomes","project_id_text":"OFHS260113","organisation_name":"University of Bristol","organisation_sector":"Academic Institute","lay_summary":"This study will develop free-to-use software that helps researchers link differences between people\u2019s genomes with diseases and other health-related factors.\nThe software will be designed to enable the inclusion of people with different genetic ancestries in scientific studies, meaning researchers can make best use of all the participants enrolled in the Our Future Health programme. It will be shared with the wider scientific community to facilitate research by other scientists, which will help avoid the duplication of effort, and makes the best use of public money.\nThe shortfalls that this project is designed to address are twofold. Firstly, historically, these types of studies have been conducted with largely people of European ancestry as participants. There are several problems with this, including: results not being generalisable to all people, less power to detect important results than might otherwise be the case, and the fact that people with non-European ancestries are likely to be under-served by medical and scientific advances, which is prejudicial to equity in health research. The second shortfall is that scientists often must \u201creinvent the wheel\u201d to some extent when carrying out research. By developing and sharing code we also hope to alleviate this burden for other researchers. Until recently, most scientific studies looking at links between genetic DNA differences and health or disease have mainly included people whose genetic ancestry comes from Europe. By \u2018genetic ancestry\u2019, we mean the paths through a person\u2019s family tree by which they have inherited their DNA. This lack of diversity is a problem for two reasons. First, findings from these types of studies (known as genome-wide association studies or GWAS) may not apply to people from other genetic ancestries. Second, it can lead to inequity or unfairness in health research. Recent work has shown that including people from different genetic ancestries in research can help scientists make new discoveries. This is because some features of DNA differ between people from different genetic ancestries. For example, some DNA differences are more common in some groups than others. Also, some DNA differences are more likely to be inherited together than others and these patterns can differ between people from different genetic ancestries. These differences create both challenges and opportunities when carrying out studies that include people from more than one genetic ancestry. However, scientists currently lack user-friendly tools that bring together the analyses needed to carry out these studies.","technical_summary":null,"latest_approval_date":"2026-09-08 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":null,"public_benefit_statement":"This study will benefit the public by developing tools and methods that normalise the inclusion a greater diversity of people in a type of scientific study (GWAS) which is widely used and is proven to help improve human health. Our aim is that this will improve equity in health research.\nUntil now, people of non-European genetic ancestry have arguably been underserved by the scientific and medical advances that have come about through GWAS.\nThe tools and methods will be made public for other scientists to use, which we hope will represent an efficient and equitable use of publicly funded research.","data_sensitivity_level":null,"project_start_date":"2026-11-16 12:00:00","project_end_date":null,"access_date":null,"accredited_researcher_status":null,"confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":null,"legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":null,"organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":null,"access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":281,"team_id":86,"application_id":null,"applicant_id":null,"sector_id":3,"status":"ACTIVE","datasets":[{"id":888,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:45:29.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:45:29.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:44","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Baseline Health Questionnaire Data","dataset_version_ids":[980]},{"id":890,"datasetid":"5dcd7eb3-6b4a-4c11-9b8c-63bc7d0c0026","pid":"b9ac6f4a-06fc-4a86-b327-3b484acd81f9","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:44:35.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:44:35.000000Z","deleted_at":null,"active_date":"2026-06-01 11:03:04","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Genotype Data","dataset_version_ids":[981]},{"id":993,"datasetid":null,"pid":"f3e1819e-ee38-4ded-b747-06d9e40f09c1","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-11-26T13:59:02.000000Z","updated":"2026-06-08T09:43:46.000000Z","submitted":"2024-11-26 13:59:02","published":null,"created_at":"2024-11-26T13:59:02.000000Z","updated_at":"2026-06-08T09:43:46.000000Z","deleted_at":null,"active_date":"2025-06-12 14:36:43","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Clinical Measurements Data","dataset_version_ids":[1140]},{"id":1769,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":1067,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2026-06-01T10:18:57.000000Z","updated":"2026-06-04T13:44:39.000000Z","submitted":"2026-06-01 10:18:57","published":null,"created_at":"2026-06-01T10:18:57.000000Z","updated_at":"2026-06-04T13:44:39.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:54","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Participant Geographies Data","dataset_version_ids":[2047]}],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false},"team":{"id":86,"pid":"7edbcc67-610e-4234-a7ea-47e0e7f0b64c","created_at":"2024-10-08T11:18:56.000000Z","updated_at":"2026-06-19T09:14:29.000000Z","deleted_at":null,"name":"Our Future Health","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":"\/teams\/1729869846_ofh_logo_hdruk_2000x1000.jpg","member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":true,"is_question_bank":false,"is_provider":false,"url":null,"introduction":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health is the UK's largest ever health research programme. It is designed to enable the discovery and testing of more effective approaches to prevention, earlier detection and treatment of diseases.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"The programme is collecting and linking multiple sources of health and health-relevant information, including genetic data, across a cohort of up to 5 million people. It is recruiting participants from all ages, backgrounds and communities to create a cohort that truly reflects the UK population.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health will create a world-leading resource for researchers from universities, charities, the NHS and companies involved in health research to undertake discovery research on early indicators of disease. Researchers will also have the opportunity to re-contact participants on a risk-stratified basis for secondary studies.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Find out more on the Our Future Health website: \"},{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/ourfuturehealth.org.uk\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/ourfuturehealth.org.uk\/\"}]}]}","dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Our Future Health dataset, please use the following link.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":4047,"created_at":"2026-11-18T15:19:37.000000Z","updated_at":"2026-11-18T15:21:39.000000Z","deleted_at":null,"active_date":"2026-11-18 15:21:39","non_gateway_datasets":[],"non_gateway_applicants":["Daphna Fenchel"],"funders_and_sponsors":[""],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Maternal Health and Wellbeing During Pregnancy and the Postnatal Period in Women with autism, ADHD, and other neurodevelopmental conditions","project_id_text":"OFHS260126","organisation_name":"King's College London","organisation_sector":"Academic Institute","lay_summary":"This study will look at the health of women with autism, Attention-Deficit\/Hyperactivity Disorder (ADHD), and related developmental conditions such as learning disabilities, developmental coordination disorder, tic disorders, and intellectual disabilities. Specifically, we will examine health-related experiences during pregnancy, childbirth and after having a baby. We want to understand whether these women are more likely to experience physical health problems (e.g. high blood pressure, preeclampsia) or mental health difficulties (e.g. depression, anxiety) compared to women not diagnosed with neurodevelopmental conditions. We will also explore how pre-pregnancy health could affect these experiences during and after pregnancy. Physical and mental health during and after pregnancy play a key role in the wellbeing of both mothers and their babies. Women with neurodevelopmental conditions, such as autism and ADHD, often experience additional physical and mental health difficulties, including anxiety, depression, sleep problems, epilepsy, and other long-term health conditions. These co-occurring conditions may increase the risk of complications during pregnancy and affect the health of both mother and child. Women with neurodevelopmental conditions may also face barriers to accessing healthcare and support that meet their needs. Despite this, relatively little is known about their experiences of pregnancy, childbirth, and early motherhood, or how their wider health profiles influence mother and baby wellbeing.\nThis study will use population-scale data from Our Future Health, including linked health records and self-reported health information, to better understand the experiences of women with neurodevelopmental conditions before, during, and after pregnancy. By examining a broad range of physical and mental health, we aim to build a more comprehensive picture of maternal wellbeing and needs. The study will improve our understanding of how neurodevelopmental conditions interact with other aspects of health across this period and help identify opportunities for more effective healthcare monitoring, support, and treatment.","technical_summary":null,"latest_approval_date":"2026-11-10 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":null,"public_benefit_statement":"Physical and mental health problems during and after pregnancy are becoming more common. At the same time, more women identify\/are diagnosed as having autism and ADHD. Understanding how these women experience pregnancy and early motherhood is therefore increasingly important. This study will help identify which women may be at greater risk of health problems during pregnancy, complications during birth, or mental health difficulties before or after having a baby. This could help healthcare professionals recognise, target and manage these. The findings could also help make maternity services more inclusive and accessible for women with autism and ADHD. In the longer term, this could improve the health and wellbeing of both mothers and babies and help ensure that all women receive the care and support they need.","data_sensitivity_level":null,"project_start_date":"2026-11-11 12:00:00","project_end_date":null,"access_date":null,"accredited_researcher_status":null,"confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":null,"legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":null,"organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":null,"access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":281,"team_id":86,"application_id":null,"applicant_id":null,"sector_id":3,"status":"ACTIVE","datasets":[{"id":888,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:45:29.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:45:29.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:44","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Baseline Health Questionnaire Data","dataset_version_ids":[980]},{"id":889,"datasetid":"5255a7ee-e9da-4d77-80bc-3e1a4bf35c50","pid":"723886b5-1229-4e8e-811f-1879ebcb365d","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:43:01.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:43:01.000000Z","deleted_at":null,"active_date":"2025-04-29 10:45:48","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Linked Health Records Data","dataset_version_ids":[888]},{"id":993,"datasetid":null,"pid":"f3e1819e-ee38-4ded-b747-06d9e40f09c1","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-11-26T13:59:02.000000Z","updated":"2026-06-08T09:43:46.000000Z","submitted":"2024-11-26 13:59:02","published":null,"created_at":"2024-11-26T13:59:02.000000Z","updated_at":"2026-06-08T09:43:46.000000Z","deleted_at":null,"active_date":"2025-06-12 14:36:43","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Clinical Measurements Data","dataset_version_ids":[1140]}],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false},"team":{"id":86,"pid":"7edbcc67-610e-4234-a7ea-47e0e7f0b64c","created_at":"2024-10-08T11:18:56.000000Z","updated_at":"2026-06-19T09:14:29.000000Z","deleted_at":null,"name":"Our Future Health","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":"\/teams\/1729869846_ofh_logo_hdruk_2000x1000.jpg","member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":true,"is_question_bank":false,"is_provider":false,"url":null,"introduction":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health is the UK's largest ever health research programme. It is designed to enable the discovery and testing of more effective approaches to prevention, earlier detection and treatment of diseases.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"The programme is collecting and linking multiple sources of health and health-relevant information, including genetic data, across a cohort of up to 5 million people. It is recruiting participants from all ages, backgrounds and communities to create a cohort that truly reflects the UK population.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health will create a world-leading resource for researchers from universities, charities, the NHS and companies involved in health research to undertake discovery research on early indicators of disease. Researchers will also have the opportunity to re-contact participants on a risk-stratified basis for secondary studies.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Find out more on the Our Future Health website: \"},{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/ourfuturehealth.org.uk\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/ourfuturehealth.org.uk\/\"}]}]}","dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Our Future Health dataset, please use the following link.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"laravel_through_key":4047,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false}],"applications":[]},{"id":4046,"created_at":"2026-11-18T15:19:36.000000Z","updated_at":"2026-11-18T15:20:26.000000Z","deleted_at":null,"active_date":"2026-11-18 15:20:26","non_gateway_datasets":[],"non_gateway_applicants":["Yang Luo"],"funders_and_sponsors":[""],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Understanding the combined effects of genes, lifestyle and the environment across common chronic diseases","project_id_text":"OFHS260175","organisation_name":"University of Oxford","organisation_sector":"Academic Institute","lay_summary":"Common chronic diseases such as heart disease, diabetes, lung diseases, and immune-related diseases are influenced by a mixture of factors, including our genes, lifestyle and the environment in which we live. We still do not fully understand how these factors work together or why they affect some people more than others.\n\nOur aim is to understand how genes, lifestyle and environmental factors combine to influence disease risk. We will use information from Our Future Health volunteers about their health, lifestyle, body measurements and genes, together with health records and environmental information such as air pollution. We will also examine whether genetic differences make some people more affected by particular environmental or lifestyle factors.\n\nThe large and diverse Our Future Health population will help us uncover patterns that may differ between groups. Our findings could help identify modifiable factors that could reduce disease risk and identify people who may benefit most from earlier prevention. In the longer term, this could support more personalised approaches for disease prevention. Many factors linked to poor health are already known, including smoking, diet, physical activity, body weight, air pollution and social circumstances. However, these factors are often studied separately . In everyday life, people experience many of them together, and their effects may also depend on a person\u2019s genes.\n\nWe still do not fully understand which combinations are more important for health or why the same exposure affects people differently. We will study chronic disease affecting the heart, lungs, body\u2019s use of food and energy, and immune system. Studying these conditions may reveal genetic, lifestyle and environmental factors that they share.\n\nOur Future Health provides a unique opportunity to study these questions in a large and diverse population by bring together information on health, genes, lifestyle, and the environment. This will also help uncover patterns missed when risk factors are studied separately, examine differences between groups, and highlight common pathways across diseases.\nBy identifying shared and potentially changeable factors, this research could help reveal groups who may be more affected, and support better disease prediction and more effective and fairer approaches to prevention.","technical_summary":null,"latest_approval_date":"2026-10-13 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":null,"public_benefit_statement":"Common chronic diseases such as heart disease, diabetes, and lung diseases are major causes of ill health and reduced quality of life. Many of their risk factors may be preventable, but it remains difficult to identify who is most at risk and which factors matters most.\n\nOur study could show which combinations of genes, lifestyle and environmental factors are linked to higher disease risk, and which groups may be more vulnerable. This could help identify people who may benefit most from earlier prevention. For example, people who are particularly sensitive to air pollution or the effects of smoking could potentially benefit from more targeted advice, monitoring or other preventive measures. The findings could support more targeted health advice and preventive approaches, rather than using the same approach for everyone.\n\nIn the longer term, our findings could support more personalised prevention approaches, reduce the burden on health services, and better reflect the needs of different groups. This could help reach those most likely to benefit and avoid widening health inequalities.","data_sensitivity_level":null,"project_start_date":"2026-10-30 12:00:00","project_end_date":null,"access_date":null,"accredited_researcher_status":null,"confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":null,"legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":null,"organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":null,"access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":281,"team_id":86,"application_id":null,"applicant_id":null,"sector_id":3,"status":"ACTIVE","datasets":[{"id":888,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:45:29.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:45:29.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:44","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Baseline Health Questionnaire Data","dataset_version_ids":[980]},{"id":889,"datasetid":"5255a7ee-e9da-4d77-80bc-3e1a4bf35c50","pid":"723886b5-1229-4e8e-811f-1879ebcb365d","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:43:01.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:43:01.000000Z","deleted_at":null,"active_date":"2025-04-29 10:45:48","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Linked Health Records Data","dataset_version_ids":[888]},{"id":890,"datasetid":"5dcd7eb3-6b4a-4c11-9b8c-63bc7d0c0026","pid":"b9ac6f4a-06fc-4a86-b327-3b484acd81f9","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-10-08T11:32:48.000000Z","updated":"2026-06-08T09:44:35.000000Z","submitted":"2024-10-08 11:32:48","published":null,"created_at":"2024-10-08T11:32:48.000000Z","updated_at":"2026-06-08T09:44:35.000000Z","deleted_at":null,"active_date":"2026-06-01 11:03:04","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Genotype Data","dataset_version_ids":[981]},{"id":993,"datasetid":null,"pid":"f3e1819e-ee38-4ded-b747-06d9e40f09c1","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":4777,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2024-11-26T13:59:02.000000Z","updated":"2026-06-08T09:43:46.000000Z","submitted":"2024-11-26 13:59:02","published":null,"created_at":"2024-11-26T13:59:02.000000Z","updated_at":"2026-06-08T09:43:46.000000Z","deleted_at":null,"active_date":"2025-06-12 14:36:43","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Clinical Measurements Data","dataset_version_ids":[1140]},{"id":1769,"datasetid":"09cfdc3c-ee13-4152-bae3-de92dd83a9a7","pid":"2adab6a1-0228-416d-b4b9-ed7a6e1efad5","source":null,"discourse_topic_id":0,"is_cohort_discovery":false,"partner_context":"HDRUK","commercial_use":0,"state_id":0,"uploader_id":0,"metadataquality_id":0,"user_id":1067,"team_id":86,"views_count":0,"views_prev_count":0,"has_technical_details":1,"created":"2026-06-01T10:18:57.000000Z","updated":"2026-06-04T13:44:39.000000Z","submitted":"2026-06-01 10:18:57","published":null,"created_at":"2026-06-01T10:18:57.000000Z","updated_at":"2026-06-04T13:44:39.000000Z","deleted_at":null,"active_date":"2026-06-01 11:02:54","create_origin":"MANUAL","status":"ACTIVE","name":"Our Future Health Participant Geographies Data","dataset_version_ids":[2047]}],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false},"team":{"id":86,"pid":"7edbcc67-610e-4234-a7ea-47e0e7f0b64c","created_at":"2024-10-08T11:18:56.000000Z","updated_at":"2026-06-19T09:14:29.000000Z","deleted_at":null,"name":"Our Future Health","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":"\/teams\/1729869846_ofh_logo_hdruk_2000x1000.jpg","member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":true,"is_question_bank":false,"is_provider":false,"url":null,"introduction":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health is the UK's largest ever health research programme. It is designed to enable the discovery and testing of more effective approaches to prevention, earlier detection and treatment of diseases.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"The programme is collecting and linking multiple sources of health and health-relevant information, including genetic data, across a cohort of up to 5 million people. It is recruiting participants from all ages, backgrounds and communities to create a cohort that truly reflects the UK population.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Our Future Health will create a world-leading resource for researchers from universities, charities, the NHS and companies involved in health research to undertake discovery research on early indicators of disease. Researchers will also have the opportunity to re-contact participants on a risk-stratified basis for secondary studies.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"Find out more on the Our Future Health website: \"},{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/ourfuturehealth.org.uk\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/ourfuturehealth.org.uk\/\"}]}]}","dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Our Future Health dataset, please use the following link.\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/research.ourfuturehealth.org.uk\/apply-to-access-the-data\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[{"id":281,"name":"Amy Peters","firstname":"Amy","lastname":"Peters","email":"amy.peters@ourfuturehealth.org.uk","secondary_email":null,"preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":null,"provider":"azure","created_at":"2024-10-08T11:14:15.000000Z","updated_at":"2026-11-18T14:22:28.000000Z","deleted_at":null,"sector_id":5,"organisation":"Our Future Health","bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":0,"terms":true,"hubspot_id":31477292673,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"laravel_through_key":4046,"rquestroles":[],"cohort_discovery_roles":[],"cohort_discovery_nhs_sde":false}],"applications":[]},{"id":3431,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:43:38.000000Z","deleted_at":null,"active_date":"2026-06-24 18:58:35","non_gateway_datasets":["TBC"],"non_gateway_applicants":["Christina Saville"],"funders_and_sponsors":["NIHR BRC"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"PREDICT-NURSE (Predicting Nurse Staffing Requirements from Routinely Collected Data)","project_id_text":"NIBDAPC_2026_0056","organisation_name":"University of Southampton","organisation_sector":"Academic Institute","lay_summary":"Aim\nUsing information about patients already held by hospitals (such as vital signs, care plans and diagnostic information) we aim to estimate the optimum number of nursing staff required on a ward, to provide a better match between patient needs (demand) and number of staff required (supply).\n\nBackground\nIf there are fewer nurses than needed on hospital wards, more patients suffer complications and more will ultimately die. However, managers do not know when patients will be admitted or discharged, nor how quickly they will recover or deteriorate. So it is hard to plan staff numbers.\n\nMost hospitals use the Safer Nursing Care Tool (SNCT) to guide staffing decisions. For this, nurses record the severity of each patient's illness, and how dependent they are on nursing care, sometimes several times per day. Maybe information already recorded about patients could be used instead.\n\nWhat we will do\nWe will develop algorithms (lists of rules for computers to follow) using patient data to predict the number of nursing staff needed on different wards. We will also survey nurses and run workshops to find out how staffing tools are used and what would help. \n\nWorking with eight diverse NHS general hospitals in England, we will extract SNCT assessments and patient data from IT systems. We will predict the SNCT assessments from information about patients on the ward at the time of the assessment. Our focus is on patients staying in hospital (inpatients rather than outpatients) and nursing staff (registered nurses and nursing support staff). \n\nWe will also extract staff rosters, patient outcome data (e.g. mortality rates and readmissions) and ask nurses whether there were enough staff on their current shift. We will use this data to test if our algorithms are valid. Our study is retrospective observational (looking backwards at what happened) and longitudinal (tracking patients over time).","technical_summary":null,"latest_approval_date":"2026-02-04 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"No","public_benefit_statement":"Priority-setting and engagement activities preceded and informed project development. As part of our recently concluded study (NIHR128056), we presented to a group of PPIE (patient public involvement and engagement) contributors from the ARC Wessex PPI Academy. The discussion highlighted a strong sense from participants that adequate staffing in the NHS was vital, and a belief from some that nursing assistants might be suitable substitutes for registered nurses. Participants were surprised by previous research results pointing to adverse effects from higher assistant staffing and were surprised at the lack of regulation around staffing numbers. \n\nWe discussed further engagement opportunities with lay representatives on our advisory group who noted that this PPI group had very particular experience \u2013 they were experienced in PPIE, older and affluent. We actively sought out a different group of non-experienced lay people, who were younger and may have fresh viewpoints and experiences of the NHS. Eleven Health and Social Care students (16-19 years old) from a local college and their tutor attended a workshop. They came from a variety of backgrounds and ethnicities, providing a good reflection of the demographics of our city. Participants discussed their concerns about low staffing in the NHS and their expectations that nursing assistants had mandatory training and that there were mandatory minimum staffing levels (both not currently met).\n\nWe also discussed the issue of using patient and nurse roster data in our projects. There was general support for use of anonymised data for research purposes by university researchers, where there was no profit motive. This encouraged us to pursue the use of routinely-collected data for this study.\n\nIn a questionnaire funded by RDS South Central Public Involvement Fund we asked 5 people who had recently stayed in hospitals for their perspectives on nurse staffing, e.g. \"What does \u201cenough\u201d nursing staff look like?\" A commonly raised issue was the importance of staff being visible and available: \"Being able to speak to a nurse if you have concerns\", \"Nurses and HCAs visible, call bells being answered\" and \"Are they providing interactive patient care or are they filling in charts, sitting at the computer or talking amongst themselves\". The conclusion of this was that patients believe that nurses being available to care for patients should be prioritised over documentation. This helped shape the current research project, which aims to remove one of nurses\u2019 documentation tasks, so making them more available to patients. We also asked what patients would not want overlooked regarding safe staffing, and the issue of having enough staff at night was raised. We will develop these questions further with our public co-Investigator as the basis of PPI activities in this project.","data_sensitivity_level":null,"project_start_date":null,"project_end_date":null,"access_date":null,"accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2026_CS_0056","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3427,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:41:43.000000Z","deleted_at":null,"active_date":"2026-06-24 18:59:15","non_gateway_datasets":["TBC"],"non_gateway_applicants":["Mikael Sodergren"],"funders_and_sponsors":["Imperial College London"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Develop a machine learning algorithm to predict in hospital falls using de-identified patient data from iCARE","project_id_text":"NIBDAPC_2025_0052","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"Hospital falls are the most common type of patient safety incident in the NHS, affecting over 247,000 patients each year in England alone. When someone falls in hospital, they face serious risks including broken bones, head injuries, longer hospital stays, and loss of independence. These falls cost the NHS \u00a3630 million annually and can have devastating effects on patients and their families.\n\nWhile most hospital falls are preventable with simple interventions like regular check-ins, helping patients move safely, and modifying their environment, identifying which patients are most at risk remains challenging. Current assessment tools, such as the Purpose T or Waterlow, rely on manual checklists that often miss important risk factors and can be inaccurate. These tools might overlook subtle changes in a patient's condition during their hospital stay that could indicate increased fall risk.\n\nThis project aims to create a more accurate, data-driven system for predicting which adults (\u226518 years old) who are admitted to hospital are at risk of experiencing a fall during the admission. We will use the iCARE database, which contains detailed information about patients' medical conditions, medications, test results, and hospital care. By applying machine learning to analyse this data, we will develop a scoring system that categorises patients by risk level (low, moderate, high) for falls. As a study that looks back at previous patients this risk will not be communicated to the affected patients. \n\nTo help inform this analysis, we shall seek to understand the accuracy of how falls are recorded in the iCARE database through matching electronic healthcare records with pseudonymised data from mandatory reports clinical staff must complete after a patient has an in-hospital fall.\n\nThis tool could help clinical teams quickly and accurately identify high-risk patients, allowing for early, targeted preventive measures such as enhanced monitoring, mobility assistance, and environmental modifications. The goal is to reduce the number of patients who fall in hospital, prevent injuries and complications, improve patient comfort and outcomes, and decrease treatment costs for the NHS.","technical_summary":null,"latest_approval_date":"2025-12-03 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"No","public_benefit_statement":"This research proposal addresses a critical gap in patient safety by developing a novel prediction tool using machine learning for in-hospital falls prevention. This project has been designed in alignment with priorities established by leading organisations such as the James Lind Alliance, National Institue for Health and Care Excellence (NICE), World Health Organisation (WHO), and the NHS Patient Safety Strategy.\n\nThe identification and prioritisation of this research topic has been developed in line with the James Lind Alliance Multi-morbidity in Later Life Priority Setting Partnership, which involved 354 participants including patients, carers, and healthcare professionals. This partnership specifically identified falls prevention as a top research priority, with participants emphasising the need for better prediction and prevention approaches to reduce the devastating impact of falls on patients and families.\n\nThe significant clinical need for this research is underscored by the enormous scale and impact of in-hospital falls. In England alone, over 247,000 inpatient falls occur annually, making them the most frequently reported patient safety incident in NHS healthcare. These falls cost the NHS \u00a3630 million annually and result in over 4 million additional bed days. The human impact is equally devastating: falls contribute to 130 annual deaths, over 2,000 hip fractures requiring surgical intervention, and significant long-term disability affecting patient independence and quality of life.\n\nCurrent risk assessment tools, such as the Purpose T or Waterlow, have fundamental limitations that compromise patient safety. NICE Guidelines explicitly recommend against using numeric risk scoring tools due to insufficient evidence of clinical utility. Systematic reviews reveal these tools achieve inadequate discriminative ability, with most tools showing area under the cure values below 0.7 and poor positive predictive values of only 2-62%. This means most patients identified as \"high-risk\" will not actually fall, whilst many who do fall are missed entirely.\n\nThe complications of in-hospital falls are profound and costly. More than 90% of hip fractures result from falls, with one-fourth of elderly hip fracture patients dying within six months. Hip fracture survivors experience 10-15% decrease in life expectancy and significant decline in quality of life. Fear of falling affects patient willingness to engage in rehabilitation, creating cycles of deconditioning that increase future fall risk.\n\nIf the algorithm is successful in determining which individuals are at risk of falls, successful deployment of this algorithm and appropriate management may help reduce the likelihood of an individual having a fall. This would therefore have profound effects on quality of life, as well as potentially quantity of life.\n\nAs improving the accuracy of prediction compared to current clinical assessment is an important metric, this project will also incorporate an investigation on the accuracy of coded information that will inform the algorithm. This shall be undertaken oby matching cases to those reported through Datix and diagnostic coding. Pseudonymised data will then be imported into the iCARE environment to enable assessment of the accuracy of the coded data that will be used to inform the model. Importantly this should not overlap with the currently ongoing insightFall study but hopefully in time be complementary in improving patient stratification and outcomes.","data_sensitivity_level":null,"project_start_date":null,"project_end_date":null,"access_date":null,"accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2025_MS_0052","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3425,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:40:39.000000Z","deleted_at":null,"active_date":"2026-06-24 19:01:57","non_gateway_datasets":["N\/A - this is a consent to contact IHKB study; no data is being made available"],"non_gateway_applicants":["Chris Butler"],"funders_and_sponsors":["The UK Dementia Research Institute (DRI) and the US Alzheimer\u2019s Association (AA)"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"The causal role of neural activity in neurodegeneration (CR-NAND) - IHKB Study","project_id_text":"NIBDAPC_2025_0050","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"The aim of our research is to develop a new method for treating Alzheimer\u2019s Disease (AD), which works by stimulating a part of the brain important for memory (called the hippocampus). This is done using a form of electrical stimulation called temporal interference (TI) stimulation, delivered by electrodes (small discs capable of delivering electricity) placed on the scalp. Normally, electricity delivered in this way can\u2019t penetrate deep into the brain (where the hippocampus is located), but our new method of TI stimulation uses two sources of electricity which, when delivered together, overlap deep in the brain to stimulate the hippocampus effectively. \n \nPrevious work has shown this approach to be safe in healthy younger adults  (with no history of neurological or psychiatric illness) and those with Alzheimer\u2019s Disease, but what we do not yet know is whether it works at improving memory. This study, a clinical trial of TI brain stimulation, is designed to detect any beneficial effects of the stimulation on memory in people with Alzheimer\u2019s Disease. If a positive effect is found, this new method of brain stimulation may be a useful future treatment for Alzheimer\u2019s Disease.","technical_summary":null,"latest_approval_date":"2025-10-27 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"Yes","public_benefit_statement":"Alzheimer\u2019s Disease is a progressive and irreversible disease of the brain and the most common cause of dementia. Problems with memory are often the first sign of the condition, and over time the ability to function independently is affected. This causes significant difficulty and distress for individuals suffering with Alzheimer\u2019s Disease, as well as their families. Concerningly, the number of those with the condition is predicted to triple to 150 million globally by 2050. \n \nAt present, Alzheimer\u2019s Disease has no cure. Current treatment is limited to a few medications (e.g. donepezil, rivastigmine) which can provide some improvement in symptoms but do not alter the underlying disease process.  The latest developed drugs show more promise, but are only able to slow down, not stop, the progression of the disease. New forms of treatment are, therefore, desperately needed. We believe that non-invasive brain stimulation of the part of the brain essential for memory is a promising new approach to treating Alzheimer\u2019s Diesease. Since the stimulation requires the placement of electrodes (small discs) on the scalp, this may in practice be delivered through the use of a device that is both wearable and portable. The question as to whether stimulation will have a symptomatic effect only or alter the course of disease is currently an open one. If proven effective, brain stimulation may transform the way the disease is treated,  and significantly relieve the global burden of dementia.","data_sensitivity_level":null,"project_start_date":null,"project_end_date":null,"access_date":null,"accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2025_CB_0050","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3424,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:39:43.000000Z","deleted_at":null,"active_date":"2026-06-24 19:01:47","non_gateway_datasets":["N\/A - this is a consent to contact IHKB study; no data is being made available"],"non_gateway_applicants":["David Owen"],"funders_and_sponsors":["WHO - Urena Foundation"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Modulation of Endothelial Function in Alzheimer\u2019s Disease by  18kDa Translocator Protein - Trying to Improve Brain Blood Flow in Alzheimer's Disease - IHKB Study","project_id_text":"NIBDAPC_2025_0049","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"Alzheimer\u2019s Disease (AD) is the most common form of dementia, affecting nearly one million people in the UK. It causes progressive memory loss, confusion, and a decline in daily functioning. There is currently no treatment that slows or stops its progression. Emerging research suggests that damage to small blood vessels in the brain, particularly to endothelial cells (which are the cells lining the blood vessels), may play a role in the disease.\nNormally, when a part of the brain is active, blood flow increases to support it. In people with AD, this response is often disrupted. The purpose of this study is to find out if we can improve blood vessel function in people with AD using a drug called XBD173. This drug targets a protein in the brain called the 18kDa Translocator Protein (TSPO), which plays a role in how cells handle stress and inflammation.\n\nParticipants with Alzheimer\u2019s will receive either XBD173 or a placebo (an inactive substance) for four weeks, then switch to the other treatment after a break. Brain scans and blood tests will be used to measure how well the blood vessels are working before and after treatment. Healthy volunteers will also be recruited to help optimise the brain scan method and provide comparison data, but they will not receive the drug. Healthy volunteers must have no history or symptoms of cognitive impairment or dementia. To take part, you also need to be able to have an MRI scan, not be pregnant or breastfeeding, and not have serious lung or kidney problems. \n\nBy studying how this treatment affects brain blood flow and related biomarkers, we hope to gain insights into a new way of treating Alzheimer\u2019s disease.","technical_summary":null,"latest_approval_date":"2025-07-16 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"Yes","public_benefit_statement":"Recent evidence suggests that problems with the brain\u2019s blood vessels occur early in AD and may be involved in causing the disease. This study explores a new approach \u2014 improving the health of these blood vessels to support brain function \u2014 using a drug called XBD173 that affects a protein involved in cellular stress and inflammation.\n\nThere is an urgent need for new ways to treat AD. This study could help identify a completely new treatment target and guide future clinical trials. Although participants may not benefit directly, the findings may help develop therapies that could benefit future patients with Alzheimer\u2019s.","data_sensitivity_level":null,"project_start_date":null,"project_end_date":null,"access_date":null,"accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2025_DO_0049","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3419,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:38:43.000000Z","deleted_at":null,"active_date":"2026-06-24 19:00:48","non_gateway_datasets":["N\/A - this is a consent to contact IHKB study; no data is being made available"],"non_gateway_applicants":["David Owen"],"funders_and_sponsors":["LifeArc"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Targeting 18kDa Translocator Protein (TSPO) to improve brain endothelial cell function in cerebral small vessel disease - IHKB Study","project_id_text":"NIBDAPC_2025_0044","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"Cerebral small vessel disease (cSVD) affects the smaller blood vessels in the brain. It is common in older people and is thought to contribute to almost half of all dementia cases and at least one quarter of all strokes. It affects memory and thinking, balance, coordination and mood.\n\nTypically, blood flow to particular areas in the brain increases when the area becomes more active. This ensures that the brain gets enough blood at the right place and time. In people with cerebral small vessel disease (cSVD), this process is disrupted, and the increased blood flow in response to activity is decreased or absent. Damage to the endothelial cells is a key pathological process in cSVD. Endothelial cells form the layer that lines the inside of blood vessels, and play a crucial role in controlling blood flow and maintaining blood vessel health. The aim of this study is to find out whether endothelial cell function and blood flow in cSVD can be improved by altering the function of a protein called 18kDa Translocator Protein (TSPO). We will do this by using a drug called XBD173, which binds to TSPO.\n\ncSVD patients will be recruited from Imperial College Healthcare NHS Trust. This is a double-blind, randomised, crossover study. This means that each participant receives the drug XBD173 and a placebo at different times, the order of which is decided by chance, and neither the participant nor the researchers know which intervention they are receiving. Participants will be invited to the clinical research facility (CRF) at Hammersmith Hospital and randomised to receive the drug XBD173 or matched placebo, twice daily, for 4 weeks. After a 6-week break where no drug is taken, participants will be switched to receive the other intervention. The study visits will involve MRI scans and blood tests to assess endothelial cell function.\n\nHealthy volunteers will also be recruited to help define and optimise the MRI scanning procedure, and provide control images . They will attend for a single MRI scan and not receive the drug XBD173.\n","technical_summary":null,"latest_approval_date":"2025-04-11 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"Yes","public_benefit_statement":"Cerebral small vessel disease (cSVD) affects the smaller blood vessels in the brain. It is common in older people and is thought to contribute to almost half of all dementia cases and at least one quarter of all strokes. It affects memory and thinking, balance, coordination and mood. People with cSVD may lose their independence and require care. There is an unmet clinical need for an effective treatment for cSVD. Although cardiovascular risk factors are strongly associated with cSVD, their treatment, which is the current management strategy for cSVD, has little impact on established cSVD.\n\nParticipants will not gain any personal benefit from this research. However, information from this study could improve our understanding of cSVD and aid the development of more effective treatment.","data_sensitivity_level":null,"project_start_date":null,"project_end_date":null,"access_date":null,"accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2025_DO_0044","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3417,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:38:14.000000Z","deleted_at":null,"active_date":"2026-06-24 19:00:21","non_gateway_datasets":["ICHT iCARE Data Model"],"non_gateway_applicants":["Oshini Shivakumar"],"funders_and_sponsors":["Imperial College Healthcare NHS Trust"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Returning to dialysis after kidney transplant failure: Linking immunology and patients\u2019 experience to mortality and morbidity risk factors","project_id_text":"NIBDAPC_2025_0042","organisation_name":"Imperial College Healthcare NHS Trust","organisation_sector":"Government Agency (Health and Adult Social Care)","lay_summary":"Kidney failure happens when the kidneys can no longer filter waste and excess fluids from the blood, leading to serious health problems. Dialysis is a treatment that takes over this filtering process to keep the body functioning. A kidney transplant is a procedure where a healthy kidney from a donor replaces the failed kidney, offering a better long-term solution than dialysis. Despite advances in medications that prevent organ rejection (such as steroids and tacrolimus), many kidney transplant recipients still experience transplant failure and must return to dialysis. However, there is limited research on how these patients fare compared to those starting dialysis without a prior transplant, with existing studies showing conflicting results. Many kidney care centres now have specialized clinics for patients with failing transplants, but once they transition to dialysis, they are usually managed in general dialysis clinics where their specific needs maybe overlooked. My study aims to compare the health outcomes of patients returning to dialysis after transplant failure with those who start dialysis for the first time at a large kidney care center in the UK. There is already evidence that certain blood markers\u2014such as the monocyte-to-lymphocyte ratio (both are types of white blood cells)\u2014and quality of life scores can predict survival in dialysis patients. Other markers, like neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, have also been linked to illness and death in dialysis patients. I aim to investigate whether these easily measurable blood markers can help predict outcomes in patients returning to dialysis after transplant failure, particularly those who have been exposed to immunosuppressive medications like steroids. If these markers show strong associations, they could help identify high-risk patients, allowing for better patient care and risk management. This research will highlight the unique challenges faced by patients returning to dialysis after transplant failure, helping both doctors and patients make informed decisions to improve long-term health outcomes.","technical_summary":null,"latest_approval_date":"2025-03-10 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"No","public_benefit_statement":"This study proposal was received positively at Patient and Public Involvement discussion groups in 2022, organised via the National Kidney Federation, UK and the West London Kidney Patient Association. Participants acknowledged that transition from failed transplant to dialysis was a period of immense psychological and physical stress. In addition to predictors of mortality and hospitalisation, they recommended to consider a further study arm - a qualitative analysis of patient experience during this transition phase. ","data_sensitivity_level":"De-Personalised","project_start_date":null,"project_end_date":null,"access_date":null,"accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2025_OS_0042","sector_id":4,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3416,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:37:28.000000Z","deleted_at":null,"active_date":"2026-06-24 19:00:08","non_gateway_datasets":["ICHT iCARE Data Model"],"non_gateway_applicants":["Mikael Sodergren"],"funders_and_sponsors":["Imperial College London"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Develop a machine learning algorithm to predict Surgical Site Infections (SSI) using de-identified patient data from iCARE","project_id_text":"NIBDAPC_2024_0041","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"A surgical site infection (SSI) is a type of hospital-acquired infection that occurs in the incision created by an invasive surgical procedure. It can either affect the local area around the wound or inside the cavity where the operation is taking place (i.e. the abdomen in gallbladder surgery). \n\nSSIs are a frequent complication after surgery, affecting about 2-5% of patients. They can lead to serious health issues, such as pain, sepsis and even death. This is associated with delays in recovering from an operation, and an increase hospital costs. In the UK, SSIs make up almost 20% of all hospital-acquired infections and place a strain on the NHS. Preventing SSIs early could improve patient outcomes and reduce hospital costs, but predicting which patients are most at risk is challenging.\n\nThis project will develop a data-driven tool to help healthcare teams identify patients most likely to develop SSIs. Using detailed patient data from the iCARE database we will analyse factors like patient age, health conditions, type of surgery, and recovery progress. By applying machine learning (a type of artificial intelligence) the project will create a predictive model that estimates SSI risk for each patient. This model will categorise patients by risk level, helping clinicians decide who might benefit from extra precautions like antibiotics, improved wound care, and close monitoring.\n\nThe goal of this tool is to support better prevention of SSIs, helping patients recover more quickly and reducing the burden of infections on the NHS. This work could also provide insights for improving prediction of other types of hospital-acquired infections.","technical_summary":null,"latest_approval_date":"2025-01-02 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"No","public_benefit_statement":"Surgical site infections (SSIs) represent a significant burden for patients, healthcare systems, and society at large. This research question addressing the development of a machine learning algorithm to predict SSIs is a priority for several compelling reasons.\n\nThe identification and prioritisation of this as a research topic has been developed in-line with a prior James Lind Alliance Priority Setting Partnership on healthcare-associated infections (HAIs). The following was determined as Priority 1 in this process: \u2018How can infections be identified early?\u2019 As further explained within the rationale for the priority, early identification of infection can help with early treatment and avoid unnecessary treatment in people without infection. It can also help with isolation of people who carry communicable infections in hospital. Further studies are necessary to find out how these infections can be detected early. This proposal aims to address this question through developing a machine learning algorithm to predict SSI risk.\n\nThe prevention and early detection of SSIs have been identified as key priorities by several stakeholders and guideline bodies:\n\u2022 The World Health Organisation (WHO) has highlighted SSI prevention as a global priority in its efforts to promote safer surgery.\n\u2022 In the UK, the National Institute for Health and Care Excellence (NICE) has issued guidelines emphasising the importance of SSI prevention and early detection, as well as antimicrobial stewardship.\n\nInternational data suggests that SSIs are one of the most common causes of HAIs. In the UK, they account for anywhere up to 20% of HAIs(3). SSIs are even more common in less-economically developed countries. SSI is implicated in one-third of postoperative deaths and accounts for 8% of all deaths caused by HAIs. Furthermore, SSIs cause pain and discomfort, increase hospital stay and put patients at greater risk of secondary infectious complications. This project aims to help identify those at risk of SSIs at an earlier stage in their care pathway and with improved accuracy compared to clinician assessment. If successful, this could be used to augment the care delivered to patients helping to speed up recovery from an operation and avoid the risk of complications and death associated with SSIs. This has an important economic impact with the additional cost of treating each infected patient estimated to be \u00a310,523. The total costs to healthcare services across Europe are estimated to be between \u20ac1.47\u201319.1 billion.\n\nThe NHS in England has set targets to reduce HAIs, including SSIs, and the threat of antimicrobial resistance as part of its Patient Safety Strategy. Many healthcare facilities aim to achieve SSI rates below international benchmarks, which vary by procedure type.\n\nDeveloping a machine learning algorithm to predict SSIs using de-identified patient data has the potential to:\n\u2022 Enable early intervention and prevention strategies\n\u2022 Reduce the incidence of SSIs and their associated complications\n\u2022 Decrease healthcare costs and improve resource allocation\n\u2022 Enhance patient outcomes and satisfaction through identifying patients who are at risk of SSI, allowing for changes in the delivery of care which reduce the complications associated with SSIs\n\u2022 Improve collective goals towards reducing the impact of antimicrobial resistance.\nBy addressing this research question, we can contribute to the ongoing efforts to reduce SSIs, aligning with priorities set out in the UK by NHS England and internationally by WHO for improving patient safety and healthcare quality.","data_sensitivity_level":"De-Personalised","project_start_date":"2025-01-16 12:00:00","project_end_date":null,"access_date":"2025-01-16 00:00:00","accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2024_MS_0041","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3415,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:37:07.000000Z","deleted_at":null,"active_date":"2026-06-24 18:59:51","non_gateway_datasets":["TBC"],"non_gateway_applicants":["Dominic Marshall"],"funders_and_sponsors":["Imperial College London"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Identification of Novel Phenotypes of Acute Lung Injury Using Longitudinal Multimodal Data","project_id_text":"NIBDAPC_2024_0040","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), are life-threatening conditions where the lungs are damaged, reducing their ability to absorb oxygen. ARDS can occur due to lung issues like infections or inflammation from illnesses elsewhere in the body. Before COVID-19, ARDS accounted for about 10% of ICU cases. This increased significantly during the pandemic, as ARDS was a common cause of critical illness and death in COVID-19 patients. In the UK, approximately 20,000 people develop ARDS yearly, with nearly half not surviving. Treatment often involves ventilators and placing patients on their front (proning). However, outside COVID-19, no medications have proven effective for ARDS despite years of research.\n\nOne reason for this difficulty is that ARDS encompasses different diseases grouped together. Treatments that help one subgroup may not work for another. COVID-19 research has shown that focusing on a specific cause of ARDS can lead to new treatments.\n\nMy research aims to identify subgroups within ALI\/ARDS using clinical data and in future chest X-rays routinely collected in ICUs. Machine learning will analyze patterns from thousands of patient variables to group patients based on their condition's progression over time, called trajectories. Combining X-ray and clinical data is a novel approach, building on earlier studies using complex lab tests. Once subgroups are identified, I\u2019ll evaluate if they align with medical understanding and compare them to previous biological data findings. For example, a subgroup may represent a group of patients who become increasingly difficult to provide support on the ventilator as their lungs become more stiff. We would want to understand if these are consistent with what doctors observe.\n\nThe goal is to determine if certain treatments work better for specific subgroups, an example of subgroup would be patients who are considered higher inflammation based on fever and blood tests. A group with inflammation-driven ARDS benefit from anti-inflammatory medicines such as steroids. . In a less inflamed subgroup steroids may be harmful as they can increase risk of infection. This approach minimizes harm from non-targeted treatments and advances personalized medicine.","technical_summary":null,"latest_approval_date":"2025-01-02 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"No","public_benefit_statement":"This research benefits the public by advancing personalized medicine for acute respiratory distress syndrome (ARDS), a critical condition affecting thousands each year. By identifying specific patient subgroups and tailoring treatments to their unique needs, it can improve survival rates, reduce harm from ineffective therapies, and optimize healthcare resources. The approach uses existing ICU data and innovative machine learning methods, making it cost-effective and widely applicable. Ultimately, this work paves the way for more precise, effective care, improving outcomes for critically ill patients and their families.\n\nI have discussed this research extensively with my PPIE panel during the preparation of my MRC application and in advisory panel meetings since. The PPIE panel members agreed that in addition to the standard metrics such as improved survival from ARDS, shorter length of stay, less time on a ventilator and fewer complications of ICU would be important. Further they indicated that being able to describe a an individuals likely clinical trajectory would be helpful in their expectations and understanding of what would happen to them or their family member.","data_sensitivity_level":null,"project_start_date":null,"project_end_date":null,"access_date":null,"accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2024_DM_0040","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3414,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:36:43.000000Z","deleted_at":null,"active_date":"2026-06-24 18:58:26","non_gateway_datasets":["ICHT iCARE Data Model"],"non_gateway_applicants":["Jonah Andrew Corcoran Rodgus"],"funders_and_sponsors":["Imperial College London"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Investigating Trends in Antimicrobial Resistance Among the Key Bacterial Pathogens Causing Infections in Intensive Care Units Across Imperial College Healthcare NHS Trust Cites During the SARS-CoV-2 Pandemic","project_id_text":"NIBDAPC_2024_0039","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"Antimicrobials kill or prevent the growth of bacteria. Antimicrobial susceptibility testing (AST) data show how well different antimicrobials work against different bacteria, helping doctors choose the right treatment. AST data are crucial in both clinical and research settings, and they can be used to help predict genomic (genetic) causes of antimicrobial resistance (AMR).  The main aim of this project is to investigate how the AST data has changed between 2020-2023, in which parts of the hospitals these changes are seen, and whether it links in with resistance genes identified in genomic data from specific bacteria, e.g., Klebsiella pneumoniae. For isolates which show the highest levels of antimicrobial resistance, we will look to see what risk factors there are that may have led to this, such as recent use of antibiotics, or particular health conditions.","technical_summary":null,"latest_approval_date":"2024-12-16 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"No","public_benefit_statement":"Infections are becoming more resistant to the antimicrobials available, and there is an increasing reliance on reserve antimicrobials. In the most resistant cases, patients are dying from infections for which no antimicrobials can be found that work. This has been classified as a public emergency by the World Health Organisation (WHO), and a key priority by NHS England.\n\nThe data analysed in this project will help to identify which patient groups are getting the more antimicrobial resistant (AMR) disease, and help to link it to the bacterial genomic (genetic) causes of that antimicrobial resistance that have already been identified. This will allow clinicians to prioritise the reserve antibiotics for those patients that really need them, and to ensure antibiotic supplies are available where they are needed.\nThis will directly benefit the care of patients attending Imperial College Healthcare NHS trust, as the results will be fed back to local clinicians (particularly specialists in treating infections) to help inform the best local antimicrobial policies to treat patients, and to help their access to the antimicrobials they need to treat more resistant infections.\n\nMore broadly, the public will benefit as outcomes from this project will help to inform public health strategies to treat and prevent antimicrobial resistance.","data_sensitivity_level":"De-Personalised","project_start_date":"2025-02-19 12:00:00","project_end_date":null,"access_date":"2025-02-19 00:00:00","accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2024_JACR_0039","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3412,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:36:16.000000Z","deleted_at":null,"active_date":"2026-06-24 18:57:44","non_gateway_datasets":["ICHT iCARE Data Model"],"non_gateway_applicants":["Mikael Sodergren"],"funders_and_sponsors":["Imperial College London"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Develop a machine learning algorithm to predict pressure injuries using de-identified patient data from iCARE","project_id_text":"NIBDAPC_2024_0037","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"Pressure ulcers, also known as bedsores, are a common but preventable condition that can affect people who are immobile, such as patients in hospitals. They occur when prolonged pressure on the skin cuts off blood flow, leading to painful sores that can become infected. Pressure ulcers impact around 700,000 people in the UK each year, including 20% of hospitalised patients. They can lead to serious health issues, extended hospital stays, and high treatment costs. For the NHS, managing pressure ulcers costs an estimated \u00a31.4 to \u00a32.1 billion each year.\n\nWhile most pressure ulcers are preventable with simple interventions, such as regularly repositioning patients or using specialised mattresses, identifying those most at risk remains challenging. Current assessment tools often rely on manual checklists, which can miss important risk factors. For example, these tools might overlook pre-existing health conditions that affect a patient's movement or sensation. They can also miss changes in a patient's health that occur during their hospital stay, such as low blood pressure or anaemia.\n\nThis project aims to create a more accurate, data-driven system for predicting who is at high risk of developing pressure ulcers. We will use the iCARE database and by applying machine learning\u2014a type of artificial intelligence\u2014to analyse this data, we will develop a scoring system that categorises patients by risk level (low, moderate, high) for pressure ulcers.\n\nThis tool could help healthcare teams quickly and accurately identify high-risk patients, allowing for early, targeted preventive measures. The goal is to reduce the number of patients who develop pressure ulcers, improve patient comfort and outcomes, and decrease treatment costs for the NHS. This approach could also pave the way for using data-driven tools to improve other areas of patient care.","technical_summary":null,"latest_approval_date":"2024-12-16 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"No","public_benefit_statement":"This research proposal addresses a critical gap in pressure injury prevention by developing a novel prediction tool using machine learning. This project was designed is alignment with priorities established by leading organisations such as the James Lind Alliance, European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance, and the American College of Physicians. \n\nPrevention has been identified as the highest care goal for patients who have experienced pressure ulcers. In this context, the James Lind Alliance Priority Setting Partnership has highlighted the following as a specific research priority: \u2018Is using a pressure ulcer risk rating scale better than clinical judgement in preventing pressure ulcers and is there a best scale?\u2019 This priority is based upon previous systematic reviews of the literature which have highlighted that data on the effectiveness of existing tools to help predict and prevent pressure injury is uncertain.\n\nThe significant clinical need for this research is underscored by the high prevalence and associated costs of pressure injuries. In the UK alone, 700,000 individuals are affected annually, incurring a daily cost of \u00a33.8 million to the NHS. Current risk assessment tools have limitations in predictive accuracy, highlighting the need for innovative solutions. The proposed project, informed by data from iCARE would hope to provide a more accurate tool, which not only can help prediction of pressure ulcers in a research setting, but lead to reduction in pressure ulcers through integration into clinical care.\n\nThe complications of pressure injuries are costly. These include increased risk of mortality, with 4.2% of stays where pressure injury is the primary diagnosis and 11.6% of stays with secondary pressure injuries ending in death. Pressure injuries can also result in pain, local or systemic infection, psychological stress, and reduced quality of life. The effect on psychological health and quality of life extends to family and caregivers due increased dependence on their help. This results in prolonged hospital stays (5-8 days per pressure injury) and higher readmission rates, leading to increased healthcare costs. Treating pressure injury costs the NHS more than \u00a33.8 million every day. In 2004 the estimated annual cost of pressure injury care in the UK was \u00a31.4-2.1 billion per year, and the mean cost per patient of treatment for a grade IV pressure injury was calculated to be \u00a310,551 a year. It is therefore likely that current costs to the NHS are higher.\n\nPressure injuries are avoidable causes of harm and care to prevent new pressure injuries or progression typically involve inexpensive changes to delivery of care compared to the cost of the cost of treatment. Despite the development of many manual risk assessments, there is minimal high-quality evidence of their effectiveness, particularly in changing outcomes. The improvement in the availability and quality of artificial intelligence algorithms informed by data from iCARE in disease diagnosis and risk assessment may lead to a step-change in improvement for many conditions, including pressure injuries. Through developing improved measures to assess the risk of pressure injury, we therefore hope this can lead to earlier intervention, reducing its incidence. This would lead to individual benefits for affected patients, but also considering the substantial healthcare costs associated with pressure injuries should also be a key priority of the wider public.","data_sensitivity_level":"De-Personalised","project_start_date":"2025-01-16 12:00:00","project_end_date":null,"access_date":"2025-01-16 00:00:00","accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2024_MS_0037","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3411,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:35:55.000000Z","deleted_at":null,"active_date":"2026-06-24 18:57:22","non_gateway_datasets":["N\/A - this is a consent to contact IHKB study; no data is being made available"],"non_gateway_applicants":["Onn Min Kon"],"funders_and_sponsors":["Commercial"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"A double-blind, randomized, placebo-controlled trial in participants with chronic obstructive pulmonary disease (COPD) to evaluate the impact of vapendavir on the development of lower respiratory tract symptoms following rhinovirus challenge - IHKB Study","project_id_text":"NIBDAPC_2024_0036","organisation_name":"Imperial College Healthcare NHS Trust","organisation_sector":"Government Agency (Health and Adult Social Care)","lay_summary":"People who smoke and have chronic bronchitis and emphysema (now recognised as Chronic Obstructive Pulmonary Disease, or COPD) often experience a worsening of their symptoms (an \u2018exacerbation\u2019) after they catch a cold. However, this does not occur in every individual with COPD, and not every cold leads to an exacerbation or illness. \n\nThe aim of this research is to test a new therapeutic drug (vapendavir) in a double blinded placebo-controlled Phase 2a clinical trial that may act to reduce or even prevent the increases in symptoms in individuals with COPD when they catch a cold. A double blinded, placebo controlled clinical trial means that neither the patient nor study team are aware which patients are receiving the investigational drug or placebo, to remove any possible bias. A phase 2a clinical trial is a type of study that is looking to investigate the safety and effectiveness of a treatment, providing a \u201cproof of concept\u201d for an investigational medicine\n\nThe study will involve participants experiencing an infection with a common cold virus (not everybody who gets given the virus gets infected). Depending on whether, and how quickly participants\u2019 symptoms develop, they may be assigned at random to take an experimental drug (vapendavir) or placebo for 7 days. By doing this, we will be able to determine if the possible increase in symptoms individuals with COPD may experience when they get a cold is improved by treatment with vapendavir.\n\nIf successful, the drug vapendavir could have a large impact on how we may treat individuals with COPD in the future. In addition, we will have the opportunity to measure a number of different proteins (called biomarkers) to better understand how the treatment works, and how virus infections cause a worsening of symptoms in people with COPD.\n\nAs the trial is nearly completed to recruitment, we have not done any study specific patient involvement and engagement prior to submission, however we are going to commit to disseminating results using lay language to the public and key COPD stakeholders through various channels. We will also commit to involving and engaging the public for any future research proposals.","technical_summary":null,"latest_approval_date":"2024-10-25 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"Yes","public_benefit_statement":"This research is important because viral infections, particularly those caused by rhinovirus (which is the primary cause of the common cold), significantly impact people with stage II COPD. In people with COPD, viral infections like rhinovirus can cause sudden worsening of symptoms, known as exacerbations. These exacerbations are one of the main reasons patients with COPD end up in the hospital, experience a reduced quality of life, and see their disease progress more rapidly.\n\nStudies show that between 40% and 50% of COPD exacerbations are caused by rhinovirus infections. These viral exacerbations can lead to further loss of lung function. Even though there are treatments available for COPD, such as bronchodilators (which help open the airways), inhaled corticosteroids (which reduce inflammation), and antibiotics (which fight bacterial infections), these treatments are not fully effective for managing exacerbations caused by viruses and often come with significant side effects. \n\nThis study suggests that developing a treatment specifically aimed at stopping rhinovirus could significantly improve outcomes for COPD patients. The idea is that if an anti-rhinovirus treatment is given early during an infection, it could prevent or limit the virus from replicating and spreading. This would, in turn, reduce the severity and duration of the exacerbation.The potential benefits of such a treatment include fewer exacerbations, less need for hospital visits, and better long-term health for COPD patients. By reducing the frequency and severity of exacerbations, this approach could not only improve the day-to-day lives of COPD patients but also help lower healthcare costs by reducing hospitalizations and the need for intensive treatments.","data_sensitivity_level":null,"project_start_date":null,"project_end_date":null,"access_date":null,"accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2024_OMK_0036","sector_id":4,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3405,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:35:12.000000Z","deleted_at":null,"active_date":"2026-03-31 10:13:00","non_gateway_datasets":["ICHT iCARE Data Model"],"non_gateway_applicants":["Michelle Willicombe"],"funders_and_sponsors":["Imperial College London"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Demographic and outcome of patients presenting with respiratory viral infections","project_id_text":"NIBDAPC_2024_0030","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"During the COVID-19 pandemic it was recognised that certain people, e.g. those with a compromised (weak) immune system, had a worse prognosis as they were unable to mount an appropriate immune response to fight off the infection.  To try and improve the severity of symptoms, these people were given additional booster vaccines and also community treatment should they become infected.  \nPeople with compromised immune systems are also at increased risk of severe infections from other common viruses, such as flu and a virus called respiratory syncytial virus (RSV).  There has been recent approval for the use of a vaccine against RSV.  The department of health plan to roll it out to young children and elderly people (70 years or older) in 2024.  People with compromised immune systems under the age of 70 are not currently being considered for the vaccine.  This is because there is currently no data which assesses the risk of RSV in the immune vulnerable.  In a similar approach, the type of annual flu vaccine which is offered to people is based on age rather than how vulnerable their immune system is.\n\nAt Imperial College Healthcare NHS Trust, when patients present with respiratory symptoms and are admitted they are swabbed with a kit which tests for COVID-19, flu and RSV at the same time.  Using the iCARE data set, we will therefore be able to assess the features (e.g. age, ethnicity, co-morbidities (other health conditions people live with) of the patients who got swabbed, tested positive for each viruses and if they were admitted to hospital, how long for and whether they became severely unwell.  This will help support or disprove the current planned policy of basing flu and RSV vaccines on age alone, and the COVID-19 vaccine on age plus immune compromised state.","technical_summary":null,"latest_approval_date":"2024-02-06 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"No","public_benefit_statement":"This study aims to assess whether people younger than 70 years, including those with weakened immune systems experience severe symptoms related to RSV, and  therefore may benefit from vaccination which will improve their health and quality of life.","data_sensitivity_level":"De-Personalised","project_start_date":"2024-02-28 12:00:00","project_end_date":null,"access_date":"2024-02-28 00:00:00","accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2024_MW_0030","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3403,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:34:52.000000Z","deleted_at":null,"active_date":"2026-03-31 10:13:00","non_gateway_datasets":["TBC"],"non_gateway_applicants":["Mona El-Bahrawy"],"funders_and_sponsors":["Imperial College London"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Management of tumours with fertility preservation and enhancement","project_id_text":"NIBDAPC_2023_0028","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"Many women now prefer to delay having children, often for career or personal reasons, until they are older.  As we age, the chances of developing different diseases, including tumours, rises. There are also some tumours that can develop at a young age.  The treatment of tumours may require surgery and \/ or additional drug- based or radiation-based treatments, which can affect a patient\u2019s ability to have children (fertility).  As some patients may still wish to have children, there are ways to protect their fertility during treatment. This is known as fertility sparing, and there is interest in further developing methods to preserve and enhance fertility.   Our project will collect data about patients of childbearing age who develop tumours.  This will include information on the type of tumour and treatment received, patient demographics (e.g. age, gender, ethnicity), and the outcome of any fertility sparing and \/ or enhancing treatment received. This will help us gain a better understanding of factors affecting fertility in patients with tumours and work towards identifying predictive models to help develop patient tailored treatment plans to maximise patients\u2019 chances of preserving their fertility.","technical_summary":null,"latest_approval_date":"2023-10-27 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"No","public_benefit_statement":"I have been a core member of the Gynaecological Oncology Multidisciplinary Team at Queen Charlotte and Chelsea \/ Hammersmith Hospital, which is effectively the West London Gynaecological Cancer Centre, and also receives referrals from other parts of the UK and overseas.  In our practice we see many patients coming with tumours during the child bearing age and looking for fertility sparing options.\n\nIn addition I have special clinical and academic interest in borderline ovarian tumours, which most commonly affects women in the child bearing age group.  Borderline ovarian tumours are an uncommon type of ovarian tumours that are not frankly malignant, but the patient my have similar tumours developing again after initial tumour removal or may develop cancer subsequently.  That is why although these tumours are not classified as cancer they ideally require being surgically treated as cancer.  For the past 17 years I have been studying these tumours to identify markers that can help predict their behaviour and hence be able to identify patients who can safely have fertility preservation surgery without high risk of disease progression.  Contributing to and leading on studies in our trust and also national multicentre studies I developed an appreciation to the pressing need of young patients to have the option of preserving fertility with minimal risk of disease progression.  I am also a member of the advisory board of Ovacome, a charity with focus on ovarian tumours, and in that role I had an opportunity to further appreciate the importance of this aspect of tumour management from communicating with patients and patient representatives.","data_sensitivity_level":null,"project_start_date":null,"project_end_date":null,"access_date":null,"accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2023_NEB_0028","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3402,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:34:19.000000Z","deleted_at":null,"active_date":"2026-06-24 18:54:29","non_gateway_datasets":["ICHT iCARE Data Model"],"non_gateway_applicants":["Bernard Hernandez"],"funders_and_sponsors":["Imperial College London"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":["https:\/\/doi.org\/10.1016\/j.artmed.2024.103008","https:\/\/doi.org\/10.1016\/j.landig.2025.01.010"],"project_title":"Analysis of longitudinal laboratory data to develop models for the assessment, diagnosis, and prediction of bacteremia, bloodstream infection, and sepsis","project_id_text":"NIBDAPC_2023_0027","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"Blood-related infections are a significant concern in healthcare, as they can lead to serious medical complications. The presence of bacteria in the bloodstream, which can result from various sources such as wounds, surgical procedures, or other infections is denoted as bacteremia. When these bacteria start to multiply in the bloodstream and the immune response mechanisms fail or become overwhelmed, it causes a bloodstream infection that can spread throughout the body. The infection can evolve into septicemia which is a severe response to infection, often characterized by widespread inflammation, organ dysfunction, and a high risk of mortality, particularly in critical care units. Therefore, early identification and management of these conditions is paramount in healthcare settings to mitigate its potentially dire consequences. \n\nThe increased adoption of electronic health records has provided a valuable opportunity for healthcare providers and researchers to improve the diagnosis and treatment of these conditions. Currently, when it comes to making computer programs that assist doctors in diagnosis, treatment, or prediction of possible complications, these three conditions (bacteremia, bloodstream infection and sepsis) are usually handled separately. Creating separate computer programs might produce accurate results during the development phase but often they do not perform effectively in real-life medical scenarios. Furthermore, employing various systems that yield divergent and at times conflicting outcomes may generate confusion among medical professionals, prompting uncertainties or hesitance in adopting these tools. Since these conditions are all related and occur in a sequence or a cycle, it's crucial to research and develop computer programs that consider all of them collectively. This would help improve understanding on the underlying mechanisms and temporal dynamics of these conditions, how they relate to each other, how they progress over time and what are the most relevant risk factors. Ultimately, these findings could pave the way for the development of a computer program that effectively assists clinicians in prevention, early detection, and treatment covering the different steps needed to manage blood-related infections and ultimately improve patient outcomes.","technical_summary":null,"latest_approval_date":"2023-11-14 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"No","public_benefit_statement":"Our project to develop a computer program to support healthcare professionals in the management of bacteremia, bloodstream infections, and sepsis is driven by a clear understanding of the profound impact these conditions have on patients and the broader public. From discussions with health care professionals, patients, and the public, it has become clear that this research question is important and offers substantial benefits to the patients and the public at large. \n\nLooking at it from the healthcare professional\u2019s point of view, identifying the signs of sickness or deterioration early is crucial the help patients get better. The project focuses on the use of a computer program to quickly look through patient information like vital signs, test results and medical history to facilitate healthcare professionals to diagnose and start the treatment as soon as possible. Early detection can significantly reduce the risk of complications and mortality, benefiting both individual patients and the public health system. Moreover, not all cases progress in the same way and the appropriate treatment strategy varies based on patient-specific factors. By helping doctors make personalized treatment plans, we enhance the effectiveness of treatments and reduce the chances of treatment failure. This approach, in which the patient is at the centre, not only improves outcomes but also reduces the unnecessary use of antibiotics, addressing the global concern of antimicrobial resistance. In addition, these conditions can rapidly escalate, leading to severe illness and death if not managed effectively. By assisting healthcare professionals make informed decisions, we aim to mitigate the progression of the disease, which hopefully reduces the number of patients affected severely and therefore the mortality rates. This benefit extends to patients, families, and the broader community, as it eases the burden on healthcare resources and reduces the emotional and economic toll of these diseases.\n\nFrom the patient\u2019s point of view, this project aims to create a piece of technology to give doctors the tools they need to identify the signs of these conditions sooner and select a personalized plan so that patients get better without suffering any complications. The notion of detecting infections at an early stage resonates profoundly, as it facilitates the identification and treatment of health issues before they escalate. The concept of facilitating healthcare professionals to select a personalized plan that considers the patient\u2019s individual medical history instead of the one-size-fits-all approach emphasizes a patient-centred approach which is met with reassurance. In addition, patients find interesting to know that projects like this could also help health experts learn more about these conditions and express a sense of fulfilment in knowing that participation holds the potential to contribute to broader advancements in public health practices.","data_sensitivity_level":"De-Personalised","project_start_date":"2024-02-16 12:00:00","project_end_date":null,"access_date":"2024-02-16 00:00:00","accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2023_BH_0027","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[{"id":338,"dur_id":3402,"type":null,"title":null,"status":null,"detail":null,"url":"https:\/\/doi.org\/10.1016\/j.artmed.2024.103008","created_at":"2026-09-07T14:29:39.000000Z","updated_at":"2026-09-07T14:29:39.000000Z","deleted_at":null},{"id":339,"dur_id":3402,"type":null,"title":null,"status":null,"detail":null,"url":"https:\/\/doi.org\/10.1016\/j.landig.2025.01.010","created_at":"2026-09-07T14:29:39.000000Z","updated_at":"2026-09-07T14:29:39.000000Z","deleted_at":null}],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3400,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:33:40.000000Z","deleted_at":null,"active_date":"2026-06-24 18:56:14","non_gateway_datasets":["ICHT Patient Falls Dataset"],"non_gateway_applicants":["Rachel Tao"],"funders_and_sponsors":["ICHNT Health Innovate Charity"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Using Routine Data to Monitor Why Patients Fall in Hospital","project_id_text":"NIBDAPC_2023_0025","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"Falls are the most frequently reported patient safety incident in hospitals in England. The impact of falls includes distress, pain, injury including head injuries and bone fractures, loss of confidence, loss of independence, and death. Patients who suffer a fall in hospital have longer stays and are more likely to fall at home after hospital discharge. \n\nThis project will address two problems:\n1. While we know much about falls risk factors in older people, comparatively less is known about why falls happen in specific under-represented groups including people with learning disabilities and those who do not speak English.\n2. Investigation and monitoring of inpatient falls currently relies on manual review of medical notes and incident reports by clinical staff -  a process that is labour intensive and leads to long time lags between fall events and safety improvement initiatives.\n\nThe aims of this project are to better understand why specific specific under-represented patient groups fall in hospital and to develop and test an IT system that will provide automated, near-real-time reports to Imperial College Healthcare NHS Trust on the circumstances and mechanisms of all inpatient falls. These reports will support coordinated safety monitoring and improvement efforts by staff across the Trust.\n\nThe project entails:\n\u2022 describing the characteristics of patients who have fallen in hospital (e.g. age, ethnicity, deprivation score, diagnosis, co-morbidities, clinical condition at the time of the fall)\n\u2022 analysis to identify falls risk factors and outcomes - with emphasis on under-represented groups (patients with learning disabilities, non-native english speakers: groups identified by the British Geriatrics Society and Care England for whom evidence and guidance is lacking around falls)\n\u2022 applying Natural Language Processing to patients\u2019 medical notes. Natural Language Processing is a form of Artificial Intelligence that enables insights to be extracted from free-text information. Artificial Intelligence is a set of instructions which are written in a computer program. The instructions run a computer programme which performs mathematical tests on data. The instructions that allow the AI to work are called an \u2018algorithm\u2019.\n\u2022 We will semi-automate these algorithms to provide near-real-time insights into the circumstances and mechanisms of falls to clinical and safety leads.\n\nThis work will be complemented by qualitative work (interviews) with patients and clinical staff to better understand the trends we are seeing in the data and the impacts of having near-real-time insights into why patients fall in hospital.","technical_summary":null,"latest_approval_date":"2023-05-26 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"No","public_benefit_statement":"A significant proportion of the population will be affected by falls during their lives: around one third of people over the age of 65 and more than half of people over 80 fall at least once per year.  The impact of falls includes distress, pain, head injuries, bone fractures, loss of confidence, loss of independence, and even death. Patients who suffer a fall in hospital have longer stays and are more likely to fall at home after hospital discharge. There is also a significant additional carer burden linked to falls.\n\nThis work could lead to patient\/public benefit in two ways:\n\n1. Both the British Geriatrics Society and Care England (charity representing the adult social care sector) have identified a need for further evidence and guidance on identifying and managing falls risk factors in people with learning disabilities and in those who do not speak English. Ensuring that language barriers do not increase the risk of harm to patients is an important priority for Imperial College Healthcare NHS Trust; the North-West London population is diverse, with many patients attending the Trust who do not speak English or who have English as a second language. This work will benefit patients by helping Imperial College Healthcare NHS Trust to better falls in these under-represented groups. This will contribute to developing strategies to reduce the risk of harm from falls in these patient groups (for example, if our analysis were to show that there is a higher incidence of falls in non-English speaking patients, the Trust could look at further investing in interpreting and translation services to support non-English speaking patients to engage with clinical staff around safe mobility).\n\n2. An IT system enabling near-real-time monitoring of why patients are falling in our hospitals will support the Trust to identify trends enabling them to better respond to falls and improve patient safety. Near-real-time monitoring will support coordinated falls prevention efforts across the Trust (for example, if our near-real-time reporting system was to showing an increasing number of falls linked to patients with delirium (a state of mental confusion that can be caused by being very unwell or by being given certain medications), the Trust could implement an improvement project to help clinical staff to better understand and manage the risk of falls in patients with delirium). ","data_sensitivity_level":"De-Personalised","project_start_date":"2023-09-06 12:00:00","project_end_date":null,"access_date":"2023-09-06 00:00:00","accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2023_RT_0025","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3399,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:32:49.000000Z","deleted_at":null,"active_date":"2026-06-24 18:56:33","non_gateway_datasets":["ICHT iCARE Data Model"],"non_gateway_applicants":["Alison Holmes"],"funders_and_sponsors":["Imperial College of Science","Technology and Medicine"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"Analysis of Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment to Assess the Potential Role of Therapeutic Drug Monitoring in UK Infection Management (DATA TDM study)","project_id_text":"NIBDAPC_2023_0024","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"Antimicrobials are drugs used to treat infections.  They include antibiotics like penicillins (e.g. amoxicillin), cefalosporins (e.g. ceftriaxone), carbapenems (e.g. meropenem) and many others. If antimicrobials are not used correctly, for example if the wrong drug, dose, or duration of treatment is given, then the treatment may not work. This may mean that patients don't get better.  It can also lead to the development of 'antimicrobial resistance', which is when bacteria or other microorganisms become 'resistant' to standard antimicrobials and are therefore more difficult to treat.Usually, patients are given standard doses of antimicrobials in a \u2018one size fits all' approach, which is a standard dose of the drug. This  doesn't account for potentially wide variability in response to antimicrobials between patients.  Therefore, some patients may be over- or under-dosed.\n\nThis study aims to observe patients receiving antimicrobial treatments for infections, measure the concentration of antimicrobials in their blood, and estimate the proportion who are dosed optimally.  It will also investigate a wide variety of 'patient factors' which may be associated with sub-optimal dosing.\n\nThis study will involve recruiting patients with infections at Imperial College Healthcare NHS Trust (ICHNT) and taking samples to analyse antimicrobial levels. All patients who are being treated for suspected or confirmed bacterial infections will be eligible. Groups of patients with specific diagnoses (e.g. urine tract infection) or who are being given specific antimicrobials of interest (e.g. meropenem) will be selected based on updated literature review and consensus research priority of the investigator group. Using the iCARE platform it will be possible to examine the effect of antimicrobial treatment on patient outcomes which will support the developemnt of optimised treatment guidelines.","technical_summary":null,"latest_approval_date":"2023-05-26 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"No","public_benefit_statement":"Antimicrobials are drugs used to treat infections.  They include antibiotics like penicillins (e.g. amoxicillin), cefalosporins (e.g. ceftriaxone), carbapenems (e.g. meropenem) and many others. If antimicrobials are not used correctly, for example if the wrong drug, dose, or duration of treatment is given, then the treatment may not work. This may mean that patients don't get better.  It can also lead to the development of 'antimicrobial resistance', which is when bacteria or other microorganisms become 'resistant' to standard antimicrobials and are therefore more difficult to treat. Antimicrobial resistance (AMR) poses a significant global challenge. Accurate antimicrobial dosing is needed to improve patient outcomes, limit potential sides effects and reduce the development of AMR. Currently, patients are treated according to a one dose fits all approach which does not account for variations such as the infecting organism or the health of the patients. This study will identify and examine the factors that can influence the effectiveness of antimicrobial treatment to improve patient outcomes.","data_sensitivity_level":"De-Personalised","project_start_date":"2026-02-03 12:00:00","project_end_date":null,"access_date":"2026-02-03 00:00:00","accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2023_AH_0024","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]},{"id":3395,"created_at":"2026-02-26T16:03:52.000000Z","updated_at":"2026-11-13T15:31:49.000000Z","deleted_at":null,"active_date":"2026-06-24 18:57:55","non_gateway_datasets":["TBC"],"non_gateway_applicants":["Brendan Delaney"],"funders_and_sponsors":["Innovation Grant"],"other_approval_committees":[""],"gateway_outputs_tools":null,"gateway_outputs_papers":null,"non_gateway_outputs":[""],"project_title":"LOng COvid Multidisciplinary consortium: Optimising Treatments and servIces across the NHS (LOCOMOTION) ","project_id_text":"NIBDAPC_2023_0020","organisation_name":"Imperial College London","organisation_sector":"Academic Institute","lay_summary":"This project aims to understand the clinical needs of patients with Long COVID within North West London. It forms part of a UK-wide project called the LOng COvid Multidisciplinary consortium: Optimising Treatments and servIces acrOss the NHS (LOCOMOTION).\n\nLong COVID is a condition that causes some people to continue to feel unwell many weeks after their original COVID-19 infection. Patients may have a wide range of different symptoms, including tiredness, pain, rashes and heart palpitations, and may require many different medical tests or see many different specialist doctors to receive a diagnosis and the treatment they need. As a result, it is likely that some patients may take longer to be diagnosed, or maybe miss being diagnosed at all. Similarly, patients may receive different treatments and may have better or worse clinical outcomes. \n\nThis project aims to look at how patients with a diagnosis of Long COVID in North West London receive care from their GPs and hospitals. We want to understand the sorts of appointments, clinical tests and treatments patients receive before and after their Long COVID diagnosis and to use this to understand where current services for patients with Long COVID could be improved. \n\nWe also aim to investigate how the sorts of tests and treatments patients receive vary between patient groups, based on age, gender, ethnicity, socioeconomic deprivation, the London Borough they live in and any pre-existing medical conditions they may have. This will give us a deeper understanding of where inequalities in Long COVID care may exist between patient groups and will enable clinicians to better design services in North West London to help those for whom Long COVID services may be working less well.   \n\nLong COVID is a new condition \u2013 it was unknown before the COVID-19 pandemic \u2013 and therefore across the country specialist clinics have developed to provide care to patients with Long COVID. Not all clinics operate in the same way and because it is such a new condition it is not yet clear which treatments work best for specific patients. The findings from this project with provide an important indication of how Long COVID care is being delivered across GP and hospital services in North West London.","technical_summary":null,"latest_approval_date":"2023-03-31 12:00:00","manual_upload":true,"rejection_reason":null,"sublicence_arrangements":"No","public_benefit_statement":"A recent study describes the top 10 research priority areas for Long covid, this was a Joint patient and clinician priority setting to identify the key research questions regarding the long-term sequelae of COVID-19. \n\nThis study will help inform what is currently happening in long covid assessment clinics, including, assessments, treatment and outcomes,  diagnostic tools,  the trajectory of recovery and evaluating the role of interventions, which has been identified as a key research priotiy by this consortium establishing.","data_sensitivity_level":null,"project_start_date":null,"project_end_date":null,"access_date":null,"accredited_researcher_status":"Unknown","confidential_data_description":null,"dataset_linkage_description":null,"duty_of_confidentiality":"Not applicable","legal_basis_for_data_article6":null,"legal_basis_for_data_article9":null,"national_data_optout":"Not applicable","organisation_id":null,"privacy_enhancements":null,"request_category_type":"Public Health Research","request_frequency":"One-off","access_type":"TRE","enabled":true,"last_activity":null,"counter":0,"user_id":4777,"team_id":93,"application_id":null,"applicant_id":"NIBDAPC_2023_BD_0020","sector_id":3,"status":"ACTIVE","datasets":[],"publications":[],"tools":[],"keywords":[],"outputs":[],"user":{"id":4777,"name":"Giselle Kerry","firstname":"Giselle","lastname":"Kerry","email":"Giselle.Kerry@hdruk.ac.uk","secondary_email":"giselle.kerry@hotmail.co.uk","preferred_email":"primary","email_verified_at":null,"secondary_email_verified_at":"2025-09-24 09:18:19","provider":"azure","created_at":"2025-06-05T13:51:42.000000Z","updated_at":"2026-11-19T10:31:16.000000Z","deleted_at":null,"sector_id":6,"organisation":null,"bio":null,"domain":null,"link":null,"orcid":null,"contact_feedback":0,"contact_news":0,"is_admin":1,"terms":true,"hubspot_id":128489718789,"is_nhse_sde_approval":false,"registry_digital_identifier":null,"rquestroles":["GENERAL_ACCESS"],"cohort_discovery_roles":["GENERAL_ACCESS"],"cohort_discovery_nhs_sde":false},"team":{"id":93,"pid":"d9d1f252-1f5d-45cf-b8b3-078dfaf739fb","created_at":"2024-10-08T11:19:00.000000Z","updated_at":"2026-06-22T14:33:54.000000Z","deleted_at":null,"name":"Imperial College Healthcare NHS Trust","enabled":true,"allows_messaging":false,"workflow_enabled":false,"access_requests_management":false,"uses_5_safes":false,"is_admin":false,"team_logo":null,"member_of":"ALLIANCE","contact_point":null,"application_form_updated_by":"Qresearch webapp","application_form_updated_on":"0001-01-01 00:00:00","notification_status":false,"is_question_bank":false,"is_provider":false,"url":null,"introduction":null,"dar_modal_header":"Important information about applying","dar_modal_content":"{\"type\":\"doc\",\"content\":[{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"text\":\"To apply for access to the Imperial College Healthcare NHS Trust dataset please use the following link:\"}]},{\"type\":\"paragraph\",\"content\":[{\"type\":\"text\",\"marks\":[{\"type\":\"link\",\"attrs\":{\"href\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer nofollow\",\"class\":null}}],\"text\":\"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/icare\/icare-facility\/information-for-researchers\/\"}]}]}","dar_modal_footer":null,"is_dar":false,"service":null},"application":null,"users":[],"applications":[]}],"first_page_url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=1","from":1,"last_page":105,"last_page_url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=105","links":[{"url":null,"label":"&laquo; Previous","page":null,"active":false},{"url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=1","label":"1","page":1,"active":true},{"url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=2","label":"2","page":2,"active":false},{"url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=3","label":"3","page":3,"active":false},{"url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=4","label":"4","page":4,"active":false},{"url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=5","label":"5","page":5,"active":false},{"url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=6","label":"6","page":6,"active":false},{"url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=7","label":"7","page":7,"active":false},{"url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=8","label":"8","page":8,"active":false},{"url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=9","label":"9","page":9,"active":false},{"url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=10","label":"10","page":10,"active":false},{"url":null,"label":"...","active":false},{"url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=104","label":"104","page":104,"active":false},{"url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=105","label":"105","page":105,"active":false},{"url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=2","label":"Next &raquo;","page":2,"active":false}],"next_page_url":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur?page=2","path":"https:\/\/api.healthdatagateway.org\/api\/v1\/dur","per_page":25,"prev_page_url":null,"to":25,"total":2605}